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1. Summary 
 In current clinical practice, there is a constant need for autologous tissue for 
reconstruction. In head and neck reconstruction, the drive by reconstructive surgeons 
to provide the best functional and aesthetic outcome for their patients has made 
microvascular free tissue transfer the preferred reconstructive method1. These flaps 
have superior versatility compared to regional pedicled flaps and their reliability2 
makes them increasingly popular . The pectoralis major flap3,4, radial forearm flap5,6, 
osteocutaneous fibula flap7 are some of the more commonly used flaps for head and 
neck reconstruction. Advances in microsurgical techniques have allowed a wider 
repertoire of autologous tissue transfer. In the recent years, perforator flaps like the 
anterolateral thigh flap8 have gained popularity. However, one major drawback of 
using these autologous tissues is donor site morbidity. A steep learning curve often 
limits its use, especially in the case of perforator flaps. Furthermore, the harvested 
flap often requires some surgical manipulation and adjustments in spatial positioning 
in order to obtain the desired shape to fit the defect. Prefabrication can address this 
problem by constructing a three-dimensional (3D) scaffold that matches the defect 
before it is implanted into its vascular pedicle. 
Currently, in vitro engineered tissue that has been re-implanted in vivo is 
either avascular or thin enough to obtain sufficient nutrients by diffusion from 
surrounding vessels9,10. Tissues that need to be transferred from one part of the body 
to another as three-dimensional constructs with their own vascular supply need to be 
prefabricated by either wrapping vascularised soft tissue around the construct11 or 
placing a vascular pedicle within the tissue to be transferred12 so that angiogenic 
outgrowth may allow successful microvascular transfer subsequently. Therefore, a 
distinct alternative would be one using tissue engineering techniques consisting of a 
scaffold and mesenchymal stem cells, with a vascular supply. The generated 
prefabricated flap would address the many pressing problems that harvesting 
autologous tissue entails. 
Current techniques have shown that generating vascularised soft tissue is 
possible by either using an arteriovenous (AV) shunt loop or an arteriovenous bundle 
as a vascular carrier13, 14. Polylactic-co-glycolic acid (PLGA) has been shown to be 
suitable matrix for seeding human dermal fibroblastsc in in vitro studies carried out by 
our laboratory15 PLGA, in the form of Dermagraft®, has also been used clinically to 
treat diabetic foot ulcers16,17. Therefore, it is possible that by combining a ligated 
arteriovenous bundle with PLGA seeded with fibroblasts, a prefabricated vascualrised 
soft tissue flap can be produced. 
This experiment aims to generate a prefabricated vascularized soft tissue flap 
in vivo by providing vascular supply through an arteriovenous bundle. Specifically, 
we want to; Evaluate PLGA, enveloped by a cell sheet composed of fibroblasts, as a 
suitable scaffold for a prefabricated flap; Document angiogenesis and proliferation of 
seeded cells within the scaffolds. With this model, we hope that we may be able to 
tissue engineer a prefabricated vascularized flap without the use of intrinsic soft 
tissue. Eventually, larger and more complex prefabricated flaps may be generated 
with novel tissue engineering techniques. 
2. Abbreviations 
CFDA SE   carboxy-fluorescein diacetate, succinimidyl ester 
DIEP   Deep inferior epigastric artery and vein 
ECM   Extra cellular matrix 
EPC   Endothelial precursor cell 
FGF   Fibroblast growth factor 
HDF   Human Dermal Fibroblast 
MAPC   multipotent adult progenitor cells  
MSC   mesenchymal stem cells 
PCL   Polycaprolactone 
PDGF   platelet-derived growth factor  
PLGA   Polylactic-glycolic acid 
PLGA-c  Polylactic-glycolic acid with collagen 
RFF   Radial forearm flap 
rhBMP  recombinant human bone morphogenetic proteins  
STSG   Split thickness skin graft 
TGF   transforming growth factor 
TRAM   Transverse rectus abdominis myocutaneous  
VEGF   vascular endothelial growth factor  
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Table 1. Cultivability and invitro proliferation potential of different primary human 
cells 
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4. List of Figures 
Fig.1  Reconstructive ladder demonstrating the fundamental principle in planning  
closure of a defect from simple to more complex.  
Fig. 2 Chemical structure of PGA 
Fig. 3  Chemical structure of PLA 
Fig. 4  L(+) and D(-) enantiomers of lactic acid 
Fig 5.  Each cell sheet was folded over a scaffold from four sides in sequence to  
obtain a dermal equivalent. 
Fig. 6  Synthesis of poltcaprolactone from e-caprolactone  
Fig 7A Right inguinal exposure demonstrating the vascular pedicle (paper arrow) at 
the point of ligation immediately proximal to the origin of the inferior 
epigastric vessels, before truncation. Note the fat pad swung up that is 
supplied by the inferior epigastric vessels.  
Fig 7B Construct immediately after implantation. It “sandwiches” the pedicle and is 
surrounded by PCL envelope 
Fig. 8 Construct in-situ just before harvest (After 4 weeks of implantation). Paper 
arrow shows the location of the pedicle which was pulsatile and patent in all 
constructs at the point of harvest 
Fig.9A Unseeded PLGA-c construct, immediate pot harvest. Showing the retained 
morphology of the construct with no significant shrinkage or contraction of 
the construct after 4 weeks of implantation. 
Fig. 9B Seeded PLGA-c construct, immediate post harvest. Morphology is 
maintained with no significant shrinkage. 
Fig 10A and 10B. viewed under normal light and fluorescence microscopy, 
respectively (Olympus IX 70). These two representative images are taken of 
the same slide at 10X magnification, with and without fluorescent filter. 
Fluorescence is seen in image 7B as evident by the green specks. The site 
corresponds to the PLGA-c fibres. 
Fig. 11A and 11B Higher magnification (40X) view of another slide showing more 
clearly the association between fluorescent cells and PLGA-c fibres. Note the 
bluish material over the bottom half of fig. 8A. This corresponds to where 
fluorescent cells are seen in fig 8B.  
Fig 12. Mean cell count, 3 high powered fields (hpfs) per slide, using 4 different 
sections. C1: control 1, unseeded PLGA-c construct; C2: control 2, unsseded 
PLGA-c construct; S1: specimen 1, PLGA-c/cell sheet construct; S2: 
specimen 2, PLGA-c/cell sheet construct; S3: specimen 1, PLGA-c/cell sheet 
construct 
Fig. 13 Mean number of intact PLGA-c fibres, 3 high powered fields (hpfs) per slide, 
using 4 different sections. C1: control 1, unseeded PLGA-c construct; C2: 
control 2, unsseded PLGA-c construct; S1: specimen 1, PLGA-c/cell sheet 
construct; S2: specimen 2, PLGA-c/cell sheet construct; S3: specimen 1, 
PLGA-c/cell sheet construct 
Fig. 14A H and E slide (10X) of a representative control slide showing obvious 
PLGA-c fibres with their typical ovoid cross sections closely poacked together 
with scant interyarn cellular material. Note also the well encapsulated 
construct with no breach of tissue through the e-polycaprolactone film 
(bottom right of slide). The vascular pedicle is well seen on this slide with the 
more muscular artery next to the thin walled, red blood cell filled, vein. 
Fig 14B. H and E of a PLGA-c/cell sheet construct (10X) showing much less remnant 
PLGA-c fibres and larger amounts of cellular material almost homogenously 
distributed throughout the sample. Again the vascular pedicle is well seen 
with the artery and vein next to each other.  
Fig. 15A H and E slide of a representative control specimen at high power (40X) 
showing mainly of PLGA-c fibres with little tissue formation or cells in 
between the fibres. The PLGA-c fibres remained largely intact with no evidence 
of inflammation or foreign-body reaction. Note the closely packed and 
relatively well preserved PLGA-c fibres seen in their cross sections. 
Fig. 15B . H and E of a PLGA-c/cell sheet construct (40X) showing much less 
remnant PLGA-c fibres and larger amounts of cellular material almost 
homogenously distributed throughout the sample. In contrast to fig 13A, the 
blue PLGA-c fibres have mostly disintegrated. 
Fig 16. Mean number of capillaries counted over 3 high powered fields (hpfs) per 
slide, using 4 different sections. C1: control 1, unseeded PLGA-c construct; C2: 
control 2, unsseded PLGA-c construct; S1: specimen 1, PLGA-c/cell sheet 
construct; S2: specimen 2, PLGA-c/cell sheet construct; S3: specimen 1, PLGA-
c/cell sheet construct 
Fig 17 Seeded PLGA-c construct at high power (40X H and E) showing luminal 
sprouting from the venous lumen. Similar sprouting was noted in control 
constructs from the venous lumen. 
Fig. 18 Control construct (H and E, 40X) showing capillaries within the construct. 
These capillaries were found throughout seeded and unseeded constructs. Note 
that capillaries were also seen upto the edge of the constructs which had been 
isolated by e-polycaprolactone film from surrounding tissue and hence external 
vessel ingrowth.  
Fig 19A Masson’s Trichrome (10X) of control specimen showing scant collagen 
formation concentrated mainly around the vascular pedicle. 
Fig 19B Masson’s Trichrome (10X) of seeded specimen showing collagen fibres 
stained blue-green throughout the construct. 
 
Fig. 20A At higher power (40X, Masson’s Trichrome). Collagen fibres are noted 
mainly along the capillary walls that have grown into the unseeded PLGA-c 
construct 
Fig. 20B Seeded PLGA-c construct at higher power (Masson’s Trichrome). Collagen 
fibres are seen throughout the construct and inter-yarn spaces. The collagen 
fibres were not confined to the capillaries.  
Fig 21. Mechanism of cellular labeling by CFDA, SE. CFDA, SE is a nonpolar 
molecule that spontaneously penetrates cell membranes and is converted to 
anionic CFSE by intracellular esterases. Amine-reactive coupling of CFSE to 




5. Introduction and literature review 
5.1 Clinical background 
Reconstructive surgery has experienced tremendous advancement over the last three 
decades, with fundamental contributions of many surgeons from the fields of plastic 
and reconstructive surgery, otolaryngology-head and neck surgery, neurosurgery, oral 
and maxillofacial surgery, and general surgery. Reconstructive surgery helps patients 
of all ages and types - whether it's a child with a birth defect, a young adult injured in 
an accident, or an older adult with a problem caused by exenteration of tumour. 
Reconstructive surgery is performed on abnormal structures of the body, caused by 
birth defects, developmental abnormalities, trauma or injury, infection, tumours, or 
disease. It is generally performed to improve function, but may also be done to 
approximate a normal appearance 
The traditional concept of the “reconstructive ladder”18 begins defect analysis with a 
hierarchical approach to the suitability of techniques to a particular defect, 
emphasizing simplicity, ascending from simple to complex (Fig. 1). It begins at the 
bottom rung with primary closure reconstruction, progressing to skin grafts, local 
flaps, through regional flaps, distant flaps, and on to microvascular free tissue transfer 
of composite blocks of tissue at the top of the ladder. One must realize however that a 
patient need not be brought through all or most of these steps and that often the 
patient is advanced directly to microvascular free tissue transfer from the initial 
preoperative planning phase. These principles though valuable and almost always 
justified, may not be applicable when certain functional and aesthetic considerations 
call for a more complicated procedure. These considerations are most evident 
following ablative procedures for cancer where restoration of function and optimal 
aesthetic outcome is required. For instance, anterior oromandibular reconstruction 
after composite resection is most appropriately reconstructed with a free tissue 
transfer technique as oppose to primary closure or use of a regional flap. Conversely, 
advanced techniques should not be applied in simpler defects when primary closure 
or local flaps may suffice. Defect considerations include volume, composition (skin, 
soft tissue, bone), location (proximity to vital structures, need for external/internal 
surfaces), and general status (i.e. previously operated, irradiated, infected). Functional 
considerations include the provision of sensibility, bone stock for skeletal framework 
and osteointegration, secretory mucosal surface and pliability. 
Free Tissue Transfer 
Distant Tissue Transfer 
Local Tissue Transfer 
Skin Graft 
Direct Tissue Closure 
Healing by Secondary Intention 
Fig.1 Reconstructive ladder demonstrating the fundamental principle in planning closure of 
a defect from simple to more complex. 18 
 
The limitations of the regional flap for reconstruction of more complex soft tissue 
deformities combined with the advancements in microvascular free tissue transfer 
over the last two decades has led to the broad application of free tissue transfer in 
reconstruction. It has provided the single most important contribution to 
reconstruction of the head and neck patient, restoring patients to an unprecedented 
degree of form and function19. Advances in anaesthetic management and monitoring 
during microvascular free tissue transfer allow these procedures to be performed 
safely with reproducible results. Microvascular free flaps enables the reconstructive 
surgeon to replace more complex soft tissue and bony tumour resection with nearly 
identical tissue types (e.g. mucosa, bone, sensate skin), volumes, and character. Many 
of the most significant drawbacks inherent to pedicled myocutaneous transfers can be 
more adequately addressed through the use of a single-stage microsurgical free tissue 
reconstruction.  
The “free flap” is a composite block of tissue (fascia, muscle, fat, bone, skin, visceral 
conduit) perfused by a defined anatomic vascular pedicle and its subsequent 
myocutaneous or fasciocutaneous perforating vessel19. It is free of limitations 
imposed by the requirements of an attached pedicle and is not restricted by tissue 
types that are available for transfer via locoregional pedicles. Consequently, the 
variety of tissue sites available for tissue transfer has led to more aesthetic and 
functional reconstruction. Microvascular free tissue transfer has also allowed ablative 
surgeons to extend their resection techniques in more radical directions with both 
curative and palliative intent, mainly because of the assurance that the reconstruction 
will be able to provide the reliability and versatility required to overcome the 
morbidity of resection.   
Although the technique of free tissue transfer is complex and time consuming, the 
numerous advantages include stable wound coverage, improved aesthetic and 
functional outcomes, and reduced donor site morbidity compared to pedicled flaps. 
Since the introduction of free tissue transfer in the 1960s, the success rate has 
improved substantially and currently is 95-99% among experienced surgeons20-21. 
Free tissue transfer is currently used for the reconstruction of complex defects and 
disorders throughout the body.  
Refinements in mandibular reconstructions have led to the use of the free fibular flap, 
which results in improved appearance and function of the neomandible. The use of 
the muscle-sparing free transverse rectus abdominis myocutaneous (TRAM) and deep 
inferior epigastric artery and vein (DIEP) flaps in breast reconstruction allows for 
excellent shape and contour of the breast mound while minimizing donor site 
morbidities related to abdominal strength and contour. The use of innervated free 
muscle flaps successfully has restored upper extremity and hand function and the 
ability to generate facial animation in incidents of nerve and muscular dysfunction. 
Free tissue transfer nevertheless has its limitations. Donor site morbidity is often 
troublesome and not all flaps allow the incorporation of composite tissue (e.g. bone, 
mucous membrane, cartilage). Studies examining donor site morbidity after fibula 
free flap highlight the following short-term and long-term results after free tissue 
transfer22:  Partial loss of donor site STSG (3%) Ankle stiffness (41%) Donor site 
pain (28%) Ankle instability (3%) Peroneal nerve motor loss (7%) Peroneal nerve 
sensory loss (24%) Decreased knee extension (14%) Decreased flexion strength 
(22%). Another disadvantage of the fibula free flap is the limitations of the soft tissue 
component of the flap. The skin islands' poor arc of rotation relative to the bone and 
its unpredictable vascularity are factors in this limitation. Patients with severe 
peripheral vascular disease may not be candidates for flap harvest if the lower limb 
vasculature is involved. Studies examining donor site morbidity after RFF flap 
highlight the following short-term and long-term results with their accompanying 
rates of frequency23:  Partial skin graft loss (16%) Tendon exposure (13%) Delayed 
healing of STSG donor site (22%) Fracture of the radius at bone harvest site (17%) 
Sensory loss in distribution of the superficial radial nerve (32%) Restricted forearm 
function (16-100%, dependent upon existence of fracture and size of flap harvested) 
Vascular compromise of the hand is the most devastating complication related to 
harvest of the RFF flap. This occurs when insufficient collateral circulation via the 
ulnar artery exists. Use of the preoperative Allen test, in which the distal perfusion of 
the hand is ensured while occlusion of the radial artery is performed, reduces the risk 
for postoperative vascular insufficiency though not absolutely.  
In an attempt to address some of the limitations of free tissue transfer, surgeons have 
introduced prefabrication, tissue expansion and increasingly tissue engineering 
techniques. These techniques attempt to enhance and broaden the application of free 
tissue transfer so as to achieve the “ideal” flap. Although there currently is no “ideal” 
flap, there is constant endeavour to achieve some if not all of the ideals of an “ideal” 
flap. These ideals include ease of dissection, ability to vary the size and thickness of 
the flap, the option of having composite tissue combined with the flap, a long and 
decent calibre pedicle, minimal donor site morbidity, not having to reposition the 
patient for flap harvest and obtaining a compatible tissue match between the donor 
and recipient sites.  
This thesis summarizes the current status of free tissue transfer with specific emphasis 
on prefabricated flaps. Tissue engineering with regards to its current and potential 
future role in clinical practice is also reviewed. Current knowledge on vascularized 
tissue engineering is examined and a brief discussion on scaffolds used in tissue 
engineering is made. The experiment attempts to bridge the gap between avascular 
tissue engineered grafts and prefabricated flaps by demonstrating that there is a 
potential for creating a prefabricated tissue engineered flap for eventual clinical use 
that will not only meet all the ideals of an “ideal” flap but may also have other 
pertinent applications in cell and tissue transplantation.    
 
5.2 Prefabricated Flaps 
Flap prefabrication was introduced clinically by Orticochea and Washio24  in 1971. 
Vascular implantation into the retroauricular conchal skin was used for subsequent 
pedicled nasal reconstruction. The term prefabrication, however was first introduced 
by Shen only in 1982 to describe the microsurgical transfer of a skin flap 
neovascularized by an implanted vascular pedicle. The technique allows for the 
creation of an “unlimited array of composite free flaps”25 that would otherwise not be 
available with standard flaps and indeed prefabricated flaps consisting of skin, 
muscle, bone, and composite tissue have been described both experimentally and 
clinically. When combined with skin expansion and a delay procedure, prefabricated 
flaps are even more versatile. This technique potentially allows any defined tissue 
volume to be transferred to any specified recipient site, greatly expanding the 
armamentarium of reconstructive options26,27. A vascular pedicle consisting of an 
artery and its venae comitantes, may be considered the smallest unit of a flap transfer. 
The concept of tissue neovascularization by the transfer of a flap or its smallest unit, 
the vascular pedicle, may be traced back to cardiac surgery in the 1930s and 40s when 
pectoral muscle, omentum and internal mammary vascular pedicles were used to 
improve and enhance collateral blood supply to the heart. Erol28 placed a full 
thickness skin graft over a femoral vascular bundle in a dog model and was able to 
transform the skin grafts into local pedicled flaps. He also applied this technique on 
ten patients using the superficial temporal vessels in nine patients and the median 
frontal vessels in one patient to create a vascularised pedicled flap for reconstruction 
of facial defects not amenable to reconstruction with local flaps due to lack of local 
tissue. 
Pribaz et al29 defined the term prefabrication as “the implantation of a vascular 
pedicle into a new territory, followed by a period of maturation and 
neovascularization, and the subsequent transfer of that tissue based on its implanted 
pedicle”. The term prelamination was used to distinguish it from prefabrication and 
was described as “a process in which tissue or other devices are implanted into a 
vascular territory before it is transferred. In flap prelamination, the blood supply is 
not manipulated”.   
Flap Prefabrication occurs in two stages. Stage 1: Implantation of vascular pedicle. A 
vascular pedicle (which includes at least the artery and its venae comitanates 
surrounded by adventitial tissue, but may also include fascia or a cuff of muscle) is 
transferred to a new area of tissue and simply implanted with the distal end ligated 
with no vascular anstomosis. Vascular connections will occur spontaneously between 
the implanted pedicle and surrounding tissue creating a new vascular territory. 
Stage 2. Flap transfer. After maturation, the neovascularized tissue is transferred 
based on the implanted pedicle. With the aid of microsurgery, it is theoretically 
possible to transfer any given tissue to any desired location in the body. Previous 
studies have reported wide variations in the time required for the development of 
sufficient vascular connections to ensure reliable survival of prefabricated skin flaps. 
Successful elevation has been reported as early as 10 days after implantation whereas 
others have found that 6 to 8 weeks is needed to ensure maximal flap survival. 4 
weeks was chosen in this study as it was the duration where most of the studies had 
reported significant neovascularization30. 
Essentially, the technique of flap prefabrication; allows vascular induction of specific 
blocks of tissue which are not naturally perfused by anatomically well defined 
vessels; creates a larger flap than would otherwise be possible; reduces donor site 
morbidity and allows evaluation of functional status before transfer of the flap27.  By 
incorporating skin, cartilage and even periostium with good osteogenic potential, 
complex prefabricated flaps can be created. Common pedicles used for 
neovascularization include the descending branch of the lateral femoral circumflex, 
superficial temporal, radial, and thoracodorsal pedicles. Greater omentum or muscle 
flap as a carrier can also be used. An alternative method is to create an arteriovenous 
shunt, which will produce sufficient neovascularization to support a free flap. 
Clinically, several authors have reported modest success using prefabricated flaps in 
the reconstruction of tracheal defects. Fujiwara, Olias, Shinohara, Homma, Cox, 
Delaere have reported variations of prefabrication techniques for tracheal 
reconstruction32-37. Pribaz26 uses flap prefabrication in two main settings; In burn 
patients who have no local options and in whom the usual fasciocutaneous flaps are 
not available because of the burn injury. Release of neck contracture is the most 
common indication and flap prefabrication is reserved for patients in whom other 
flaps are not possible. The second setting is for prefabrication of flaps with 
specialized texture, colour and characteristics (e.g. hair and composite tissue) for 
facial reconstruction. The neck, scalp and supraclavicular area can be used to provide 
specialized tissue for reconstruction of the face. Again, Pribaz advocates that 
wherever possible, known axial flaps should be considered before one proceeds to 
flap prefabrication. However, often trauma and extensive injury leaves few options. 
Various authors have also reported the use of prefabrication techniques in 
reconstruction of craniofacial defects, ear reconstruction and in urogenital 
reconstruction. 
Flap prefabrication presents the exciting possibility of custom-made flaps that better 
match the size and components of the site being reconstructed. The ability to 
neovascularize tissue expands the realms of reconstructive surgery and hence the 
reconstructive surgeon is no longer restricted to known flaps within an anatomic 
vascular territory. It is possible to custom make flaps that have better colour and 
texture match and perhaps composite flaps and flaps with specialized tissue like 
mucosa, hair or nerves may all be designed to fit into a recipient site.  Nevertheless, 
prefabrication involves the use of intrinsic tissue and inherently results in a donor site 
defect. Furthermore, fashioning three dimensional flaps from two-dimensional tissue 
remains a challenge and is not always easily achieved37. Folding a prefabricated flap 
to obtain its desired three dimensional design often results in venous congestion and 
this often requires a delay procedure, or additional means to increase venous outflow.  
 
5.3 Tissue Engineering 
Recent advances in the fields of biotechnology, cell and molecular biology, and 
biomaterials have led to the emergence of tissue engineering, an exciting new area of 
research focusing on the repair and replacement of functional mammalian tissues and 
organs. Tissue engineering was first defined at the Granlibakken workshop held in 
Lake Tahoe, California upon the recommendation of the National Science 
Foundation. The working definition as formulated is: 
 
 “The application of principles and methods of life sciences toward fundamental 
understanding of structure-function relationships in normal and pathological 
mammalian tissues and the development of biological substitutes to restore, maintain 
or improve tissue functions”  38,39 
 
Tissue engineering is a field of research which involves cooperation between multiple 
disciplines. Clinicians, cell biologists and materials engineers come together to 
identify areas in medicine where bioengineering might be able to aid in replacement 
and regeneration of missing tissue. Many medical specialties apply tissue engineering 
techniques for the development of artificial replacement tissue. Stages of 
development extend from basic research and preclinical studies to clinical 
application. Despite numerous established tissue replacement methods in 
otolaryngology, head and neck surgery, tissue engineering techniques offers novel 
ways for cell and tissue repair in this medical field.    
The patient’s own tissue is ideal in many ways for replacement of loss tissue. 
Autogenous grafts harvested from a patient’s own tissue are biocompatible, but their 
use is limited due to a lack of tissue supply, and without any amplification is of 
limited use for larger deficits or defects. Furthermore, pain and morbidity often 
develops at the donor site40. Allogeneic grafts from donors other than the host are 
more plentiful, but present the risk of disease transmission, and may trigger an 
immune response to alloantigens, resulting in host rejection. Equally problematic is 
the fact that, regardless of origin, it is difficult to form three-dimensional constructs 
from existing tissue38. 
As a result of the inherent difficulties associated with tissue grafts, several 
biodegradable polymeric systems have been used as materials for the engineering of 
biological tissues. These materials used for the engineering of biological tissues is 
broadly called scaffolds. Other components necessary for reproducing biological 
tissue include signaling molecules and cells. Successful tissue formation occurs when 
these components are placed in an appropriate environment. Tissue can be 
regenerated in vivo or ex vivo. If tissue is generated in vivo, it can be fabricated at an 
ectopic site and later transferred to the orthotopic site or fabrication can take place 
orthotopically.  
In general, signaling molecules can be delivered in three ways41; as bare protein that 
is generated using recombinant DNA technology, by delivering a gene in a vector that 
induces a cell to produce the protein, or by providing cells that produce the signaling 
molecule.  
Recombinant protein in the form of growth factors have an important role in cell 
division, cell differentiation, and matrix synthesis. Recombinant proteins are 
generally delivered on scaffolds so as to maintain a controlled supply of growth 
factors at the site of regeneration42. Alternatively, injectable carriers are being 
developed and tested for specific applications that do not ordinarily require an open 
surgical procedure or when access to the surgical site is limited. The success of 
recombinant protein therapy relies on the presence of appropriate target cells in the 
local environment that are capable of responding to the growth factors. There is 
considerable interest in using growth factors as therapeutic agents for a variety of 
applications, but the largest experience is related to bone repair using recombinant 
human bone morphogenetic proteins (rhBMP). These proteins were discovered by 
Marshall Urist in 1965 when he made the seminal observation that demineralized 
bone matrix has osteoinductive activity at ectopic sites43. rhBMP-2, for example, has 
been approved by FDA for single-level anterior lumbar. Recently, human type beta-
fibroblast growth factor (bFGF) has been available in the Japanese market for the 
treatment of decubitus and skin ulcers (Kaken pharmaceutical, Tokyo). Although 
promising, these studies along with others have also revealed the inherent limitations 
of a bare protein as a signaling molecule. The bone regenerative response to a single 
dose of exogenous protein does not appear to be as robust in humans when compared 
with the preclinical animal studies. There are several possible reasons for the 
observed decrease regenerative response: The optimal delivery systems have not been 
refined, the constitution of the scaffold may need to be altered, the diffusion and 
degradation of the protein may need to be better controlled, and facilitation of cellular 
in-growth may need to be improved. It cannot be assumed that human cells have the 
same responsiveness to recombinant proteins as compared with cells from mice, 
rabbits, dogs, and goats. Other “facilitating proteins” may be needed, which are not 
yet commercially available. These are all factors that may account for the very large 
“pharmacologic” doses of growth factors that are necessary for bone regeneration in 
patients. These “pharmacologic” doses make clinical application difficult as these 
proteins are expensive and relatively complex to synthesize. Furthermore, dosages 
required would be too high for therapeutic trials42. 
In place of introducing the growth factor directly, the gene encoding for the growth 
factor can be applied to promote tissue regeneration44. This application of gene 
therapy does not replace a defective gene per se, but rather delivers specific genetic 
information to cells to start synthesis and secretion of a gene product. Since the gene 
rather than a degradable protein is being delivered, this technique may result in higher 
and more constant levels of protein production. Cell-mediated synthesis of growth 
factors should be associated with more efficient targeting of receptors and 
consequently a more robust response. Gene therapy can be performed either by 
directly introducing the delivery vector into the anatomic site (in vivo) or by 
harvesting cells from the patient, and transferring the gene to the cells in tissue 
culture, and then transferring the genetically modified cells back into the patient (ex 
vivo). The in vivo approach can be accomplished either by direct injection into the 
site45 or by attaching the delivery vector to the scaffold46. In vivo gene therapy is 
more straight forward and simpler but is limited by inefficient gene delivery and non-
specific cellular targeting. The ex vivo approach allows for targeting of specific cells 
for gene delivery , supplies cells that directly participate in the regenerative process, 
and avoids the safety risks of directly injecting viral vectors or transfection reagents 
into the patient. The ex vivo approach however, does involve an extra step to 
manipulate and expand the cells in tissue culture and this carries the potential for 
contamination. The transduced cells can also express immunogenic viral proteins on 
the cell surface, which can incite an immune response when implanted into the 
patient. Additionally, the ex vivo approach does not eliminate the possibility of 
retroviral vectors causing insertional activation of other genes whose over expression 
can cause cancer, as seen in the French experience using ex vivo gene therapy for 
treatment of children with X-linked severe combined immune deficiency47. Progress 
in the field of gene therapy has been limited by safety concerns related to delivery 
vectors. Vectors for gene therapy can be viral but can also be nonviral. Whether tissue 
regeneration using gene therapy eventually progresses to clinical practice will likely 
depend upon whether safety concerns can be better addressed. Gene therapy will 
continue for non-tissue engineering, life-threatening conditions. As experience is 
gained and safety concerns are addressed, wider applications of gene therapy may 
occur in non-life-threatening applications such as tissue engineering. 
Cell-based therapy incorporates the direct delivery of cells and signaling molecules to 
the anatomic site for tissue regeneration. This approach is advantages because the 
cells may directly participate in the regenerative process, can be genetically modified 
by ex vivo techniques, and can potenetially develop into a variety of tissue types. The 
signaling molecules expressed by the transplanted cells have both autocrine and 
paracrine effects, which should make the regenerative process more robust48. The 
source of cells (autologous or allogeneic), type of cell (stem cell or adult 
differentiated cell), and tissue source (bone marrow, muscle, adipose, dermis or 
circulating) are important considerations when planning a cell-based therapeutic 
approach. Stem cells are characterized as being clonogenic, having the capacity for 
self-renewal, and having the ability to terminally differentiate into cells of various 
different lineages. They can further be divided into two major groups; Embryonic 
stem cells are derived from the totipotent zygote and have the ability to differentiate 
into multitude of cell types and tissues. Using embryonic stem cells is controversial 
because of the derivation and methods of procurement. In addition, there are also 
valid safety concerns with embryonic stem cells due to the extensive proliferation 
capacity and risks of tumourigenicity. Thus, regenerative approaches using stem cells 
have focused more on adult stem cells. Adult stem cells have been found in a variety 
of tissues such as bone marrow, skeletal muscle, adipose, central nervous system, 
lung and inner ear. These cells can be targeted in their native environment or isolated, 
manipulated ex vivo, and transplanted. The differentiation of adult mesenchymal stem 
cells (MSC) occurs through distinct steps regulated by cytokines and signaling 
molecules in an analogous way to the differentiation of haemopoietic stem cells. 
Plasticity has been extensively demonstrated in adult stem cells, such that the cells 
derived from mesenchymal sources can differentiate into a wide range of tissues 
following transplantation depending on the genes being expressed and the local 
environment49. Most cell-based approaches are considered experimental although 
there is an FDA-approved cell-based therapy called autulogous chondrocyte 
implantation (Carticel, Genzyme Biosurgery, Cambridge, MA) for repair of knee 
articular cartilage defects. This therapeutic process uses harvested healthy adult 
chondrocytes that are expanded in cell culture and then implanted into the cartilage 
defect.  
5.3.1 Organ/Tissue specific Tissue engineering 
Current advances in tissue engineering have allowed various tissue-specific 
constructs to be developed for potential clinical use in otolaryngology and head and 
neck surgery reconstruction. These include:  
5.3.1.1 Bone 
As an alternative to autologous bone grafts, the FDA has approved rhBMP-2 for 
anterior single level lumbar spinal fusion and BMP-7 for long bone nonunions. This 
approval was based on phase III clinical trials that showed equivalence of treatment 
and the absence of donor site morbidity/complications in the rhBMP-treated groups50. 
Clinical use of rhBMP in the head and neck have been limited to alveolar ridge 
augmentation, sinus floor augmentation, and healing osteotomy gaps during Lefort I 
advancement 51. Jones et al52 recently reported that rhBMP-2/allograft is safe and as 
effective as traditional autogenous bone-grafting for the treatment of tibial fractures 
associated with extensive traumatic diaphyseal bone loss. The study investigated the 
benefit and safety of the osteoinductive protein recombinant human bone 
morphogenetic protein-2 (rhBMP-2) when implanted on an absorbable collagen 
sponge in combination with freeze-dried cancellous allograft. Adult patients with a 
tibial diaphyseal fracture and a residual cortical defect were randomly assigned to 
receive either autogenous bone graft or allograft (cancellous bone chips) for staged 
reconstruction of the tibial defect. Patients in the allograft group also received an 
onlay application of rhBMP-2 on an absorbable collagen sponge. The clinical 
evaluation of fracture-healing included an assessment of pain with full weight-bearing 
and fracture-site tenderness. Function assessment was also administered before and 
after treatment. Radiographs were used to document union, the presence of 
extracortical bridging callus, and incorporation of the bone-graft material. Fifteen 
patients were enrolled in each group and  the mean length of the defect was 4 cm 
(range, 1 to 7 cm). Ten patients in the autograft group and thirteen patients in the 
rhBMP-2/allograft group had healing without further intervention. The mean 
estimated blood loss was significantly less in the rhBMP-2/allograft group. 
Improvement in functional scores was comparable between the groups. No patient in 
the rhBMP-2/allograft group had development of antibodies to BMP-2; one patient 
had development of transient antibodies to bovine type-I collagen. 
Experiments have revealed mixed results when using rhBMP in wound environments 
that are affected by radiation, impaired vascularization, or bacterial 
contamination53,54,55. Gene therapy for bone regeneration has shown promising results 
in clinically relevant nonprimate animal models. Cell-based therapy for bone 
regeneration has also shown promising results with case reports of human use. 
Schantz et al56 evaluated and compared tissue engineered cell–polymer constructs 
using calvarial osteoblasts and mesenchymal progenitor cells for the reconstruction of 
critical-size and three dimensionally complex cranial defects. 30 New Zealand White 
rabbits with bilateral parietal critical size defects were created. On the basis of 
computed tomography scans, customized PCL scaffolds with precisely controlled 
microarchitecture were fabricated, using a rapid prototyping technology. Bone 
marrow-derived progenitor cells and osteoblasts were isolated and expanded in 
culture. Osteoblasts (group I) and mesenchymal progenitor cells (group II) were 
seeded in combination with a fibrin glue suspension into 40 PCL scaffolds. After 
incubating for 3 days in static culture, the PCL scaffold–cell constructs as well as 
nonseeded PCL scaffolds (control group) were implanted into 15- mm-diameter 
calvarial defects. Reconstruction of the cranium and bone formation were evaluated 
after 3 months. In vivo results indicated osseous tissue integration within the implant 
and functionally stable restoration of the calvarium. Islands of early bone formation 
could be observed in X-ray radiographs and in histological sections. Implants showed 
a high cell:ECM ratio and a dense vascular network. Mechanical testing of the 
reconstructed area revealed partial integration with the surrounding corticocancellous 
calvarial bone. The amount (area) of calcification, measured by clinical computed 
tomography, indicated that cell-seeded constructs measured about 60% more than 
unrepaired or unseeded scaffolds. Seeded scaffolds indicated a yield strength which 
was about 85–90% of normal bone. The study demonstrated that customized 
biodegradable polymeric implants may be used to deliver osteogenic cells and 
enhance bone formation within critically-sized defects in vivo 
 
Clinical case reports include a 36-year-old male who sustained an avulsion of the 
distal phalanx of the left thumb57. After stabilizing the wound, periosteal cells were 
harvested from the radial bone, cultivated in osteogenic media, and loaded onto a 
hydroxyapetite scaffold for placement into a defect. The patient had excellent 
functional restoration of a stable and biomechanically sound thumb of normal length. 
A second study58 used autologous bone marrow stromal cells delivered on a 
demineralized bone matrix scaffold for repairing cranial and pyriform aperture 
defects in 11 patients. Newly formed bone was evident on CT scan imaging 3 to 6 
months postoperatively and the bone did not appear to undergo significant resorption 
up to 2 years later. Two patients required subsequent surgery and biopsies revealed a 
histological structure similar to normal bone. In contrast, areas with scaffold alone 
revealed degraded demineralized bone matrix and fibrous tissue. 
5.3.1.2 Trachea 
Long-segment tracheal defects continue to be a clinical challenge without any reliable 
surgical treatments. A tissue-engineered tracheal equivalent has been successfully 
constructed using a cell-based approach with chondrocytes and epithelial cells 
derived from sheep’s nasal septum59. The chondrocytes were loaded on a polyglycolic 
acid scaffold, which was hen wrapped around a silicon tube and implanted into the 
back of a nude mouse. Six weeks later, the epithelial cells were injected into the 
embedded cartilage cylinders after emoving the silicon tube. The implants harvested 4 
weeks later had a gross morphology that resembled the native sheep trachea. 
Histology revealed mature cartilage lined by pseudostratified columnar epithelium. 
Although biochemical assays revealed proteoglycan and hydroxyproline contents 
similar to native cartilage, a prior study using similar fabrication approach with sheep 
cells showed significantly less stress-strain curves and tensile modules when 
comparing tissue engineered trachea to native trachea. The authors have yet to report 
successful transplantation of this tissue engineered trachea into a segmental tracheal 
defect. More recently60, polytetrafluoroethylene vascular grafts were used to generate 
a composite neotrachea in a rat model. The vascular grafts were lined with a fascial 
flap based on the superficial inferior epigastric artery with full-thickness skin grafts 
on its luminal surface. The composite unit was then buried under the abdominal skin 
of 20 rats and harvested 3 weeks later. Microfil and methylene blue dye were injected 
into the superficial inferior epigastric arteries and histologic analyses were performed 
to assess microcirculation and polytetrafluoroethylene-tissue integration. All 
neotracheas were viable and without infection by the end of the study and injection 
studies demonstrated excellent circulation throughout the fascial flaps and skin grafts 
and across the polytetrafluoroethylene grafts to the overlying abdominal skin. 
Histologic analyses revealed abundant muscle-walled blood vessel ingrowth within 
the polytetrafluoroethylene grafts and all layers of the neotracheas with minimal 
inflammatory reactions. The authors concluded that they had managed to engineer a 
well-integrated neotrachea in rats that possesses rigid support, an epithelial lining, 
and reliable coverage-the prerequisites for successful trachea reconstruction. 
5.3.1.3 Cartilage  
Autologous chondrocyte implantation has now been approved by the FDA for 
treating articular  cartilage defects. Implantation of custom-shaped grafts in 
otolaryngologic and reconstructive surgery is still restricted to individual cases. In 
1997, the first attempt was made to treat a patient with an auricular defect with an 
auricle generated in vitro61. However the cosmetic result was not satisfactory since 
the bioartificial cartilage had a stable shape for only 3 weeks and was then partially 
resorbed. 3-D cartilage constructs have thus far been fabricated primarily by 
chondrocytes proliferating on biodegradable polymers. The Boston study group of 
Vacanti and Puelacher62 reported success in fabricating cartilage constructs in the 
shape of a pinna, trachea, mandibular joint as well as nasal septum. The initial 
material comprised chondrocytes isolated from bovine articular cartilage. However, 
Rotter et al63 and Haisch et al64 were able to show that these results can also be 
obtained with human cells. All these approaches involve seeding  chondrocytes onto a 
scaffold in vitro and transplanting it into an athymic nude mouse model so that the 
cell-polymer construct can develop into normal cartilage.  Vacanti et al65 used a nude 
mouse model to implant sheep chondrocytes seeded onto a polyglycolic acid scaffold 
that had been grown ex vivo for 3 months. The construct was the size and form of a 
human ear and was implanted subcutaneously into a nude mouse, which survived for 
10 months. The cartilage was stable over this period of time. However when the 
experiment was repeated in an immune competent rabbit using autogenous auricular 
cartilage, the construct was broken down by lymphohistocytic infiltration, which was 
presumably a foreign body reaction to the remaining PGA/PLA scaffold66.  
Cosmetic appearance is the measure of success in ear and nasal reconstruction. 
Engineered cartilage for the ear and nose would be most commonly indicated for 
microtia repair, partial or total rhinectomy for skin malignancies that do not require 
radiation , augmentation rhinoplasty, and cleft nasal repair. In general, the engineered 
construct must be comparable to the patient’s own cartilage and aesthetic results must 
be at least as good as current techniques. The aesthetic demands of auricular and 
nasal reconstruction require stability of the cartilaginous constructs that, as yet, have 
not been achieved     
Nevertheless, substantial advances have been made in developing stable constructs 
and the current challenge in auricular and nasal reconstruction is to develop a scaffold 
that does not incite a foreign body reaction.  
5.3.1.4 Vascular grafts 
Vascular grafts with vessel diameter ≤ 6mm are being developed in preclinical 
models67. Synthetic materials such as gortex and Dacron have been effective in larger 
vessels and are currently in widespread clinical use. Although native vessels such as 
the saphenous, internal mammary, and even the radial artery can be used for grafting 
small diameter vessels, many patients with vascular disease do not possess healthy 
peripheral vessels or their donor sites have been previously used. The critical 
functional issues in developing small diameter vascular graft are long term patency, 
burst strength, distensibility, and ability to hold suture. Presently acute animal models 
are being used. The research effort is concentrated on endothelial cell proliferation to 
coat the graft and improvement of the extracellular matrix synthesis to increase the 
burst strength. Tissue-engineered vascular autografts in larger caliber vessels have 
been applied clinically in paediatric cardiac surgery68. It is likely that basic science 
advances in tissue engineered vascular grafts will be rapidly translated to clinical 
application on a case-by-case basis. As a result, there should be rapid advances in this 
application. It is possible that vascular grafting could be used in lower flow states, 
such as free flaps, which would allow increased flexibility in placement of free-tissue 
transfers.   
Tissue engineering holds the promise of “off the shelf” parts for reconstruction of 
tissues and organs. This area has shown promising early results and opens up new 
ways to generate vital and functional organs/tissue. Various basic problems must still 
be overcomed before applying fabricated tissue. The challenges that currently face us 
are foreign body reaction to the scaffolds and regenerating tissue that will maintain its 
morphology without being distorted by cicatricial process. Furthermore, only a 
fraction of all somatic organ-specific cell types can be grown in sufficient amounts in 
vitro( Table 1).  Availability, isolation and proliferation of human stem cells thus play 
a decisive role in tissue engineering. The inadequate in vitro oxygen and nutrition 
supply is another limiting factor for the fabrication of complex tissues or organ 
systems. Without sufficient supply, cells preseeded in a scaffold for tissue 
regeneration would hardly survive following implantation of the scaffold into the 
body. For successful cell transplantation, nutrient and oxygen supply is a problem that 
is as important as immuno-isolation42. This is particularly true in clinical practice 
where patients would have been subjected to radiation, the site of implantation is 











5.4 Vasculogenesis and Angiogenesis 
Central to this project is the study and development of a vascularised tissue 
engineered construct. A summary of the current knowledge and understanding of 
vasculogenesis and angiogenesis is attempted here to provide a framework for 





In the embryo, the vascular plexus forms by two mechanisms:vasculogenesis and 
angiogenesis70. Vasculogenesis, is the process of blood vessel formation occurring by 
a de novo production of endothelial cells. Though similar to angiogenesis, the two are 
different in one aspect: the term angiogenesis denotes the formation of new blood 
vessels from pre-existing ones, while vasculogenesis is the term used for the 
formation of new blood vessels when there are no pre-existing ones. Vasculogenesis, 
was first believed to occur only during embryologic development71,72, and is the term 
for when endothelial precursor cells (angioblasts) migrate and differentiate in 
response to local cues (such as growth factors and extracellular matrix) to form new 
blood vessels. These vascular trees are then pruned and extended through 
angiogenesis. Recently, however, it was realized that vasculogenesis can also occur in 
the adult organism73,74,75. Circulating endothelial precursor cells (derivatives of stem 
cells) were identified and reportedly able to contribute, albeit to varying degrees, to 
neovascularization, such as during tumor growth, or to the revascularization process 
following trauma, e.g. after cardiac ischemia. Angioblast differentiation is controlled 
by vascular endothelial growth factor (VEGF). The lack of even a small amount of 
VEGF in the embryo leads to abnormal vascular development and death in utero. 
Therefore, it can be assumed that a certain level of VEGF is essential for normal 
vasculogenesis, with this requirement diminishing in the postnatal period. 
Vasculogenesis is responsible for the formation of the capillary structure of the 
primary vascular plexus. The subsequent branching and sprouting of this plexus is 
mainly by angiogenesis. Vasculogenesis in the adult is a relatively recent proposition. 
Asahara et al76 isolated EPCs, resident in the bone marrow, from the leucocyte 
fraction of peripheral blood. These isolated cells differentiated into endothelial cells 
in vitro. In an ischaemia model they were incorporated into sites of active 
neovascularisation. Recently, Shi74 using a canine transplant model in which the 
donor cells (in this case, presumptive circulating endothelial cells) could be readily 
distinguished from recipient endothelial cells by a unique donor DNA signature. It 
was observed that only the donor cells populated the impervious Dacron graft. These 
circulating endothelial cell precursors were derived from a subset of hematopoietic 
precursor cells (hemangioblasts) that express the transmembrane proteins CD34, 
CD133, and receptors for vascular endothelial growth factor (VEGFR-2). Recently, 
Catherine Verfaillie77 at the University of Minnesota has identified a population of 
cells that copurify with mesenchymal stem cells in the bone marrow that have the 
ability to differentiate into endothelial cells and which have in vitro functional 
characteristics essentially identical to mature endothelial cells in vivo. These 
multipotent adult progenitor cells (MAPCs) have the capacity to form a variety of 
mesoderm-derived tissues including fat, muscle, bone, cartilage, and vascular 
endothelium. Since these cells have the capacity to differentiate into endothelium or 
other mesodermal or non-mesodermalcell types, MAPCs appear to represent an even 
more primitive endothelial/mesenchymal stem cell.  Takahashi et al78,79 found that 
bone-marrow-derived EPCs were mobilised by tissue ischaemia and migrated to the 
hypoxic foci.These findings suggest that, rather than being solely due to angiogenesis, 
adult blood-vessel growth is the result of a combination of angiogenesis and 
vasculogenesis. Isner and Asahara80 postulated that vasculogenesis could play a role 
in gene therapy and ischaemia neovascularisation. EPCs can be transfected to achieve 
highly localised expression of angiogenic cytokines and matrix proteins. This could 
also be applied to tissue engineering, allowing vascularisation factors to be 
administered via the circulation to enhance the neovascularisation of engineered 
tissue in vivo. 
5.4.2 Angiogenesis 
Adult angiogenesis occurs physiologically in the ovarian cycle and during wound 
healing. It is manifest in pathological conditions such as cancer, rheumatoid arthritis, 
psoriasis and haemangiomas70. The main target vessels for angiogenic stimuli are the 
postcapillary venules and the small terminal venules. It is a multi-step process 
characterised by an orderly sequence of events82. Initially, existing blood vessels 
engorge and dilate as a result of their activation by endothelial cells. There is 
localized degradation of the subendothelial basement membrane by matrix 
metalloproteinases, allowing migration of endothelial cells into the interstitium 
through gaps in the basement membranes of the parent microvessels. The next stages 
are: the formation of immature sprouts, comprising activated endothelial cells; 
proliferation of endothelial cells behind the migrating endothelium of the sprouts; 
remodelling or digestion of the pre-existing extracellular matrix around the sprouting 
endothelium; and deposition of a new extracellular matrix. The neovessels are 
canalised with the formation of anastomoses and capillary loops, and this is followed 
by the establishment of blood flow. Pericytes are incorporated around the 
endothelium, and a continuous basement membrane forms around the new blood 
vessels. Thus, the angiogenic process requires a concerted interaction between the 
extracellular matrix, cells and growth factors to produce the required 
neovascularisation. 
5.4.3 Other Mechanisms Implicated in Angiogenesis Control 
It is important to note that the activity of an angiogenesis-regulating cytokine depends 
on the presence and concentration of other factors or cytokines in the environment of 
the responding endothelium 83. For example, exogenous factors such as hormones can 
affect conditions leading to angiogenesis 84. Isoforms of VEGF that bind to ECM-
associated heparan sulfate proteoglycans can release ECM-stored FGF-2 in a 
bioactive form85, and angiopoietins potentiate the effects of VEGF 86. Although their 
relative role in angiogenesis is not yet fully elucidated, it is now well appreciated that 
cells of the immune system such as monocytes/macrophages, lymphocytes, and mast 
cells can affect pro- and antiangiogenic balances 87. T lymphocytes were able to 
activate endothelial expression of various metalloproteinases via CD40/ CD40-ligand 
interactions. As a consequence, increased tube formation in a three-dimensional gel 
was observed 88. Based on the effect of cells of the immune system on angiogenic 
parameters and the overt neovascularization in chronic inflammatory diseases, 
antiangiogenic strategies were put forward as treatment modalities for these diseases 
as well. 
Keshet and coworkers89 identified the importance of the presence of periendothelial 
cells in the microenvironment as a control mechanism of angiogenesis. Loss of VEGF 
by androgen ablation therapy led to selective apoptosis of endothelial cells in vessels 
devoid of periendothelial cells. Based on this observation, it is now hypothesized that 
VEGF is required to maintain cell anchorage to a provisional ECM until 
periendothelial cells facilitate a more permanent mode of adhesion. Besides the 
already mentioned proangiogenic factors, VEGF, FGF-1, and FGF-2, many others 
have now been identified in various settings of physiologic and pathologic 
angiogenesis. Among them are TGF-a and TGF-b, granulocyte macrophage-colony-
stimulating factor, epidermal growth factor, interleukin-1 (IL-1), scatter factor, 
platelet-activating factor, IL-8, and substance P90. Their effects can be either directly 
or indirectly on the endothelium via activation of surrounding cells to produce other 
factors with proangiogenic activity or modulation of receptors/ receptor activities. 
Hypoxia is an important environmental factor that leads to neovascularization 
Hypoxia occurs physiologically in embryonic and developing tissues and 
pathologically in wound healing, inflammation and tumours. It induces the release of 
VEGF and upregulates VEGF receptors. A combination of nutrient (e.g. glucose) 
deprivation and hypoxia drives angiogenesis. In the case of tumor growth, however, 
cancer causing genetic changes, possibly in conjunction with environmental 
influences, are able to induce angiogenesis as well 91,92. Many oncogenes, among 
which c-myb, sis, and src, were shown to stimulate the expression of a wide variety of 
molecules that induce angiogenesis. Furthermore, mutant ras oncogenes strongly up-
regulated the proangiogenic factors TGF-a, TGF-b, and VEGF. Activated oncogenes 
can also indirectly contribute to the angiogenic phenotype by affecting the production 
and activation of BM and ECM-degrading enzymes. Tumor suppressor genes have 
now also been identified to play a role in angiogenic activities of cells. Inactivation of 
p53, for example, downregulated the antiangiogenic ECM component 
thrombospondin93,94. In nonsmall cell lung cancer, loss of p53 was associated with a 
high-vascular maturation index 95. Besides the involvement of tumor cell-associated 
changes in p53, this tumor suppressor gene also plays a role in endothelial cell-
mediated control of angiogenesis. Adenovirus-mediated overexpression of endothelial 
p53 inhibited human umbilical vein endothelial cells (HUVEC) proliferation and 
capillary network formation in vitro 96. In endothelial cells existing in atherosclerotic 
and normal human aorta, variations in p53 expression levels could be detected. 
Moreover, the multinucleated variant endothelial cells expressed a mutant p53 type, 
which may be indicative for loss of endothelial cell growth control 97. As with tumor 
cells, it is most likely that in vivo a combination of mutations in various tumor 
suppressor genes and oncogenes leads to a proliferative proangiogenic character of 
the endothelial cells. Most of the experimental data on angiogenesis control published 
so far deal with angiogenesis in cancer. The advances made in this area are of prime 
importance for understanding molecular players involved in the regulatory pathways. 
It should be realized, however, that the process of angiogenesis may be differentially 
regulated in the various disease settings. Therefore, care should be taken in 
extrapolating data on, e.g., regulatory pathways and their activators and inhibitors 




5.4.4 Maturation of the Neovasculature 
 
Endothelial cell interaction with ECM and mesenchymal cells is a prerequisite to 
form a stable vasculature. Therefore, after angiogenesis, surrounding vessel layers 
composed of mural cells (pericytes in small vessels and smooth muscle cells in large 
vessels), need to be recruited82. Cells responsible for releasing angiogenic as well as 
antiangiogenic factors include monocytes/macrophages, mast cells, lymphocytes, 
connective-tissue cells, pericytes, endothelial cells and tumour cells. These cells are 
not only the focus of cytokine action but also produce factors to modulate 
angiogenesis. Of all the cells involved, endothelial cells are the most important 
regulators. They degrade and synthesise extracellular matrix components, such as 
collagen, laminin, thrombospondin and fibronectin. They secrete cytokines and 
growth factors that have autocrine, juxtacrine and paracrine functions, leading to 
endothelial cell proliferation, elongation and orientation. Endothelial cells accomplish 
this via the synthesis and secretion of platelet-derived growth factor (PDGF), a 
mitogen and chemoattractant for a variety of mesenchymal cells. Subsequent 
differentiation of the mural precursor cells into pericytes and smooth muscle cells is 
believed to be a cell-cell contact dependent process. Pericytes resemble smooth 
muscle cells, and envelop endothelial cells in quiescent capillaries. However, they are 
absent from growing vessels, implying a role in down-regulating endothelial-cell 
proliferation. On endothelial cell-mural cell contact, a latent form of TGF-b, produced 
by both endothelium and mural cells, is activated in a plasmin-mediated process. 
Activated TGF-b can induce changes in myofibroblasts and pericytes, which may 
contribute to the formation of a quiescent vessel, ECM production, and maintenance 
of growth control. The coinciding investment of growing capillaries by pericytes with 
the deposition of BM and cessation of vessel growth during wound healing also 
indicates vessel growth regulation by pericytes 98 FGF-1 is also implicated in 
endothelial cell differentiation leading to vascular tube formation. Besides inducing 
plasminogen activator and endothelial cell proliferation and migration, FGF-1 
receptor signaling resulted in endothelial tube formation in collagen99. Angiopoietins 
and receptor tyrosine kinase Tie1 and Tie2 play critical roles in the later stages of 
angiogenesis as well. They are required for communication of endothelial cells with 
the surrounding mesenchyme to establish stable cellular and biochemical 
interactions100.  
 
5.5 Vascularised tissue engineered grafts 
Tissue currently produced by tissue engineering include skin, bone, cartilage, nerve, 
and cornea. None of them have their intrinsic blood supply and current tissue 
engineering techniques of concomitant tissue generation with a blood vessel system is 
limited. Of the approved clinical products, cartilage is avascular and the skin grafts 
are thin enough to acquire their blood supply from the recipient bed. The success of 
the neo-bladder and heart valve are partly due to the fact that these structures are thin 
enough to survive on diffused nutrition until a blood supply is established. Inadequate 
in vitro oxygen and nutrition supply is a limiting factor for the fabrication of complex 
tissues or organ systems42. The establishment of a vascular supply within tissue-
engineered constructs remains the single largest restraint on the generation of three-
dimensional structures.  
One of the current challenges in tissue engineering is the generation of large 
vascularised three-dimensional structures. This involves the creation of both a 
microvascular network and a macroscopic circulation. Ideally, the tissue should have 
a dominant artery and vein with internal diameters greater than 1mm, to permit 
reliable microsurgical transplantation. A microcirculation needs to be established to 
provide oxygenation and nutrition to the neo-tissue whilst providing an egress for 
metabolic waste products. This microcirculation is crucial for cells to survive as it is 
known that metabolically active cells must be situated within 150–200 mm 
of a blood supply in order to function properly 101. Furthermore, the integration and 
survival of tissue engineered organ replacements themselves also depend on their 
proper vascularization, which may require recreation of a supporting microvascular 
network and the ability to connect it to the body’s circulation.  
Tissue survival is therefore tenuous after implantation, if its supply is not ensured by 
a capillary network and unless an intrinsic circulation can be developed, tissue 
engineering will be restricted to thin structures such as skin, which can survive by 
diffusion until revascularisation, or structures like cartilage that are virtually vascular. 
Thus, even the small-diameter blood vessels, with walls ranging from 300 to 1000 
mm, as well as their tissue engineered replacements, require some degree of 
subservient microvasculature for proper oxygenation102. There are two main options 
of creating a vascularised tissue engineered construct and this has been classified by 
Cassell et al104 based on the origin of blood supply.  
Extrinsic blood supply is possibly the most common way in which tissue engineered 
constructs are neovascularised. The construct is implanted into a well vascularised 
bed and often this takes place subcutaneously, in the omentum or in the mesentry. 
Vascular ingrowth occurs from the surrounding tissue and the cells within the 
construct survive by diffusion until a microcirculatory network is established.  
Neovascularisation occurs via an endogenous series of events beginning with surgical 
manipulation, creating trauma and inflammation followed by a wound-healing 
response. Relative hypoxia of the tissue engineered construct tips the internal milieu 
toward angiogenic promoters/growth factors. This neovascularisation can be 
augmented by incorporating exogenous angiogenic growth factors into the 
constructs104 Other investigators have also developed scaffolds that allow rapid 
vascular ingrowth, essentially modifying the porosity of the scaffolds. The scaffolds 
may also be seeded with endothelial cells so that these cells migrate out from the 
tissue engineered construct into the implantation site, and connect with the ingrowing 
host vessels. The major drawback of relying on an extrinsic blood supply to 
neovascularise a tissue engineered construct however is that external ingrowth of the 
blood supply may need to be well established before cells can be seeded, if the 
scaffolds are preseeded, they need to be sufficiently thin to ensure cell survival by 
diffusion whilst rapid neovascularisation occurs. Further more, the tissue engineered 
constructs need to have intrinsic structural rigidity to withstand the external 
compressive forces and yet allow integration without encapsulation. 
Intrinsic blood supply is the other approach to vascularise a tissue engineered 
construct. This approach allows the engineered tissue to be transferred in a fully 
fabricated state by microvascular anastomosis to the vessels around the recipient site. 
Again there are two main methods currently being investigated to generate an 
intrinsic blood supply within an engineered construct. Firstly, researchers have 
attempted to fabricate entire organs in vitro using advanced cell-culture techniques, 
involving bioreactors or perfusion culture systems. These systems provide a constant 
flow of fresh media and nutrients within a chamber containing the tissue engineered 
construct. Variables such as oxygenation, nutrients and metabolites can be adjusted to 
optimize tissue culture conditions and may be used to direct the regulated growth of 
the new tissue. Furthermore, mechanical stress such as compression or tension can be 
applied in order to stimulate specific biomolecules. L’Heureux105 and Niklason106 
have both published their results on the successful in vitro generation of functional 
blood vessels. This bodes well for the potential development of completely in vitro 
generated vascularised tissue engineered constructs. Secondly, tissue and organs may 
be fabricated around a vessel loop or pedicle in vivo. This technique uses the body as 
a “bioreactor”, providing the tissue engineered construct with the necessary nutrients 
and oxygenation. A significant amount of research using this approach has come from 
the tissue engineering group in Melbourne, Australia. It makes use of our current 
understanding of prefabrication of flaps and the used of a chamber to generate the 
neo-tissue. It appears that in current clinical practice, the most viable approach is to 
utilize preexisting blood vessels as a vascular carrier to induce cells seeded on 
scaffolds to regenerated tissue that will have its own blood supply. Blood supply can 
be obtained through an arteriovenous shunt loop or an arteriovenous bundle. This is 
based on experimental studies107,108,109.  Clinically, arteriovenous bundles have been 
used to generate prefabricated flaps as discussed previously. In 1980, Erol and 
Spira110 provided the basis for tissue engineering using an arteriovenous shunt loop 
when they found that arterovenous shunt loops of various designs in a rat model 
developed a new capillary bed that entered skin grafts placed above them. In 1998, 
Hickey et al30 demonstrated in an implanted ligated vascular pedicle model that 
angiogenisis occured in both the implanted vascular pedicle and the small blood 
vessels within the adjacent skin bed with the sprouting of new vessels from both the 
pedicle and the bed resulting in eventual connection of these vessels. 
 In 1990 and 1995, Suzuki et al111,112 reported the clinical application of artificial skin 
dermis and showed that the pores of artificial dermis were infiltrated by cellular tufts 
of fibroblasts and capillaries when place over an open wound, and the sponge-like 
atelocollagen of the artificial dermis was gradually replaced by dermis-like tissue. 
Noting the characteristics of arteriovenous shunt loops and artificial skin dermis, 
Tanaka et al113,114 created an autologous tissue flap by combining their use in rats and 
showed that the arteriovenous loop model has inherent vascularisation properties. 
However, vascular carriers currently in use for the clinical prefabrication of skin flaps 
are fascia or muscle flaps with an arteriovenous bundle as nutrient vessels115,116. In a 
study by Tanaka et al14, comparing the potential of tissue generation and angiogenesis 
between the arteriovenous shunt loop and the arteriovenous bundle, male Wistar rats 
were divided into two main groups. In the first group, an arteriovenous shunt loop 
was constructed between the femoral artery and vein using an interpositional artery or 
vein graft. For the second group, arteriovenous bundles were created from the femoral 
artery and vein with either a flow-through design or a distal ligation type design. 
Artificial dermis was wrapped around the respective vascular carriers and evaluation 
conducted 4 weeks later. It was found that the volume of generated tissue in the shunt 
groups was significantly greater than that in the bundle groups (p<0.01). However, 
the bundle groups also showed a great potential for producing new tissue. 
Histological studies showed that cell migration between the margins of the artificial 
dermis and the arteriovenous bundle was complete at 4 weeks compared to the 
arteriovenous shunt loop model where cell migration was not complete and collagen 
fibres were sparse between the free margins of the artificial dermis and the loop 
vessels. Both the arteriorvenous shunt loop and arteriovenous bundle groups showed 
marked angiogenisis.  New capillaries were derived not only from the vasa vasorum 
of the femoral vessels but directly from the femoral vein in both the shunt and bundle 
groups. The authors conclude that “the arteriovenous shunt loop design would be 
most efficient, but found that the arteriovenous bundle also had vigorous potential for 
angiogenesis and tissue generation. The arteriovenous bundle is simpler to construct 
operatively than the arteriovenous shunt loop, does not present problems with 
thrombus formation and provides stable blood flow. Thus, the arteriovenous bundle 
seemed more useful as a vascular carrier for clinical use”. This model has certain 
advantages. The surgery creates injury with its consequent inflammatory and wound 
healing phases. Hypoxia stimulates VEGF and other proangiogenic factors. Up to this 
point, the advantages are similar to the extrinsic model of neovascularisation. 
However, the presence of an intrinsic blood supply allows the tissue engineered 
construct to be “protected” by a chamber or outer cover. This is because the blood 
supply will not be disrupted and the construct does not have to rely on the vascular 
supply of the surrounding tissue. With an outer covering, the tissue engineered 
construct may be protected from external compressive forces and it allows non-rigid 
biological constructs to mature and stabilize. This tissue engineered construct with its 
intrinsic blood supply may then be freely transferable to any suitable recipient 
vessels. Other potential advantages of this model include the possibility of designing 
the outer covering to match a specific dimension, incorporating a nerve within the 
construct to develop sensate flaps or it could serve as a reservoir for cells and growth 
factors for gene or cell based therapy.    
In this study, an arteriovenous bundle was chosen as a vascular carrier in view of the 
significant findings of the above-mentioned study.  
The theory behind the angiogenic potential of the ligated arteriovenous bundle may 
be surmised as follows; “to and fro” oscillating movement of intravascular blood and 
erythrocytes within the ligated pedicle seems to serve as initiating factors in 
angiogensis. Together with inflammation and surgical trauma, a shift towards 
angiogenesis promoting factors dominating over inhibitory factors is postulated to 
occur. These factors result in activation of the vascular endothelium or vascular 
smooth muscle cells making them more susceptible to the effect of growth factors. 
Endothelial sprouting subsequently occurs from the vasa vasorum and the lumen of 
the ligated venous system. Vascular endothelial growth factor is thought to play a 
prominent role in stimulating endothelial cells to undergo changes that ultimately 
result in the breakdown of the vascular basement membrane and adjacent 
extracellular matrix. Endothelial cells migrate into the matrix and further migration 
and establishment of cell-cell adhesion results in the formation of tubular vessels.   
The time taken and pattern of neovascularaization of prefabricated flaps have also 
been  described. Hickey et al30 described angiogenisis from both the pedicle and small 
blood vessels within the skin bed occurring within 3 days with connections between 
the pedicle and dermal vessels being present as early as 5 days after implantation of 
the pedicle.  These connections increase progressively until 2 weeks where the flap 
may survive completely when elevated. Even if the pedicle is thrombosed, he found 
that a flap may survive if elevation is delayed until at least 4 weeks after pedicle 
implantation. Survival of these flaps appears to depend upon a small number of 
critical vascular connections between newly formed vessels arising from the pedicle 
and preexisting vessels within the flap. Furthermore, given sufficient time, flaps with 
thrombosed pedicles may survive completely due to a dense vascular plexus arising 
from small adventitia vessels that develop around the pedicle. These vessels extend 
beyond the region of thrombosis and make connections with vessels within the flap, 
allowing survival of the flap. Pribaz117 also performed several experiments that 
demonstrated improved flap survival as the interval between pedicle implantation and 
flap transfer increased. Furthermore, smaller flaps, in which the ratio of the pedicle 
implantation to flap length is greater, became neovascularized in a shorter period of 
time. 
Indeed other factors thought be of importance in the use of a vascular pedicle in 
prefabricated flaps is the placement and surface contact area of the pedicle against the 
flap. It appears that methods to ensure that the longest possible pedicle length lay in 
close apposition against the dermis reduces shearing forces between pedicle and skin. 
This together with meticulous technique to ensure that the pedicle lies within the 
center of the flap has been reported to produce improved survival of prefabricated 
flaps. Pribaz et al also demonstrated that a vascular pedicle with or without a 
muscular cuff did not affect the success of the prefabricated flap.   
5.6 Scaffolds and Matrices 
Currently, generating tissue requires proliferation of human cells that are grown after 
isolation by suitable cell culturing techniques. Once a sufficient number of cells are 
available, they are seeded onto a scaffold or matrix structure. These scaffold materials 
are constructed of components of the natural extracellular matrix such as collagen or 
fibrin; or synthetic materials such as polylacticglycolic acid, polytetrafluoroethylene 
etc.  This matrices are often designed to resorb so as to avoid the long term 
disadvantages associated with implants. Natural materials may closely mimic the 
native cellular environment, whereas synthetic polymers have the advantages of being 
able to better control material properties.  
Collagen is a common natural material used for scaffold fabrication for the tissue 
engineering of dermal substitutes. It is found within the extracellular matrix of the 
dermis and is able to support the proliferation and differentiation of seeded cells when 
used as a scaffold. Examples of clinically utilized collagen based scaffolds include 
TissueFleece®, Alloderm® and Integra®. TissuFleece® is a foam made from equine 
collagen type I fibrils and is used clinically as a haemostatic agent or as a dressing for 
wounds. Alloderm® is decellularised human dermis. It is processed such that the 
epidermis and all dermal cells are removed without disruption of the collagen matrix. 
Clinically, Alloderm® has been used in the treatment of diabetic foot ulcers and for 
the coverage of free flap donor sites or burns. Integra®, originally developed by 
Yannas and Burke in 1981118, is composed of bovine collagen and shark-derived 
chondroitin-6-sulphate. It has a regular matrix architecture to that of the dermal layer 
in skin and has a superficial polysiloxane layer that maintains a barrier function 
normally provided by a cornified skin epidermis. Clinically, it is used to cover ulcers 
and wounds, especially after tangential excision in burns. Once the wound is stable, 
the silastic layer is peeled away to leave a vascularized neo-dermis suitable for 
epidermal grafting.  
The most frequently investigated biodegradable synthetic implant materials are the 
poly(〈-hydroxy acids), poly(glycolic acid) (PGA) and poly(lactic acid) (PLA). Also 
referred to as alpha polyesters, PGA and PLA degrade by hydrolytic scission into 
biological metabolites (i.e., glycolic acid and lactic acid, respectively) and have been 
approved for human use by the Food and Drug Administration. Initially used as 
resorbable sutures119,120, both PGA and PLA offer several advantages over other 
materials with respect to design flexibility. 
The synthetic polymers allow controllable degradation kinetics to suit different 
applications, allows controlled release of growth factors, demonstrate good 
biocompatibility, good mechanical properties, and are easy to handle. They can also 
be easily processed into a variety of shapes and three-dimensional structures that 
more closely mimic the native extracellular environment 121. Porosity can also be 
achieved using certain fabrication methods, allowing for essential nutrient transport 
between cells and for a high surface area to volume ratio to facilitate cell-polymer 
interactions122. Finally, the resorption rate may be controlled to meet the rate of new 
tissue formation in tissue repair by altering the polymer constituents, as low 
molecular weight polymers and less crystalline, racemic forms (i.e., DL versus L) 
degrade more rapidly than their counterparts 121. Dermagraft®, a knitted (polyglycolic 
acid), (10:90) mesh has been used to treat diabetic foot ulcers. Ng et al15 examined 
the in vitro character of several synthetic and natural dermal matrices, namely, 
TissuFleece®, Alloderm®, PLGA-PCL mesh and Chitosan. They found that 
TissueFleece®, Alloderm® and PLGA-PCL mesh supported cell attachment, 
proliferation and neo-tissue formation. TissuFleece® contracted to 10% of its original 
size while Alloderm® supported cell proliferation predominantly on the surface of the 
material. PLGA-PCL mesh promoted more homogenous cell distribution and tissue 
formation. Chitosan scaffolds did not support cell attachment and proliferation. They 
concluded that physical characteristics including porosity and mechanical stability to 
withstand cell contraction forces are important in determining the success of a dermal 
matrix material.   
Currently, matrices and scaffolds that are being developed aim to promote and control 
the cellular behaviours they induce in a more predictable and precise manner. One 
approach to achieve such biomaterials is to modify surfaces of existing materials to 
minimize the foreign body reaction and to promote normal wound healing. This 
approach is based on current understanding that cell adhesion to adsorbed proteins is 
mediated through integrin and other receptors located within the cell membrane. 
Upon adhering to the protein film, a cascade of intracellular signaling events is 
triggered. Therefore, controlling protein adsorption on the surface of biomaterials 
may be critical to controlling and directing cell responses to biomaterials. Several 
methods have been examined, from incorporating short oligopeptides that exhibit 
specific binding domains to incorporating whole proteins on the surface of the 
biomaterial. Other strategies to develop more biologically intelligent matrices 
leverages on our knowledge that the body can mend itself and regenerate new tissue. 
The only way to replace function to damaged tissue is with similar tissue that contains 
the appropriate tissue architecture of cells and ECM (extracellular matrix). A number 
of different approaches are being investigated including drug and cell delivery. In 
both cases, a carrier is required to deliver the drug to a particular site successfully 
and, in the case of cells, to provide a 3-D structure that facilitates tissue growth. Many 
different types of biomaterials have been investigated for both drug and cell carriers. 
In tissue engineering, a combination of drugs, cells, and a suitable carrier with 
tailored macroscopic properties, a well-tuned degradation profile, and specific 
biological cues may be necessary to promote normal tissue growth. 
By combining the strengths of both synthetic as well as natural materials, a better 
scaffold might be achieved that allows seeded cells to proliferate and migrate 
throughout the matrix architecture and organize a homogenously distributed ECM. At 
the same time, the synthetic material can provide the mechanical strength and be 
fabricated in the desired form. In this experiment, PLGA-Collagen matrix is used for 
these exact reasons. 
5.6.1 Polylacticglycolic acid - PLA:PGA Copolymers  
 
Polyglycolic acid (PGA)
Polyglycolic acid is the simplest aliphatic polyester (Fig2).  
 
  
Fig. 2 Chemical structure of PGA 
 
It is synthesized by ring opening polymerization from glycolide, resulting in a poly-
alpha-hydroxy derivative123. The glycolic molecule has no chiral center and therefore 
no enantiomers. Polyglycolide is polymerized from a glycolic acid dimmer. Unlike 
PLA (absorbed slowly), PGA is absorbed within weeks postimplantation due to 
greater hydrolytic susceptibility 
 
Polylactic acid (PLA) 
Polylactic acid is one of the poly-α-hydroxy acids and belongs to the group of 
aliphatic polyesters like PGA. Polylactide is polymerized from a lactic acid dimmer 
(Fig 3).  
 Fig. 3 Chemical structure of PLA 
Lactic acid possesses an asymetrically substituted carbon atom and exist in two 
enantiomers, L(+) and D(-) lactic acid. In the Fischer projection, with the carbon 
chain vertical and the carboxyl group at the top, the D enantiomer has the hydroxyl 
group on the right hand side (Fig. 4).  
 
 
Fig. 4 L(+) and D(-) enantiomers of lactic acid 
 
The two enantiomers differ significantly in their rate of biodegradation124. 
Copolymers with molecular chains consisting of repeating units of both these 
monomers can be polymerized.  The degradation rate and amorphous sections of this 
type of random copolymer increase when the proportion of D lactide increases and 
hence the physical properties of the copolymers depend on the relative amounts of L 
and D lactide125. 
PLA:PGA Copolymers 
The polymerization product of lactic acid (PLA) and glycolic acid ( PGA) is a 
copolymer of these α-hydroxy acids.  The properties of PLGAs can be modified by 
varying the copolymer ratio.  In Vicryl®, the first commercially available copolymer 
of polylactic and polyglycolic acids, the ratio of PLA/PGA was 92/8. The hydrolysis 
reaction produces glycolic and lactic acids which then enter the Tricarboxylic acid 
(TCA) cycle. In this study, the PLA/PGA ratio was 10/90. 
 
 
5.6.2 PLGA-Collagen matrix 
Biodegradable synthetic poly(α-hydroxy acids) meshes have been used as temporary 
scaffolds for the tissue engineering of skin, vessel, bladder, ligament, etc126,127. 
Dermagraft®16 and Invitra CSS™  are examples of synthetic dermal scaffolds 
currently in use. Both products use a commercial PLGA (10:90) mesh, Vicryl®, as the 
dermal scaffold. However, these synthetic bioresorbable polymers have poor surface 
properties with respect to promoting attachment, proliferation and differentiation of 
cells. Generally they are relatively hydrophobic and these hydrophobic properties, 
together with the large mesh interstices, hinder cell adhesion. Natural materials such 
as collagen and hyaluronic acid have been extensively used in a number of currently 
available tissue engineered skin products. Collagen offers the advantage of specific 
cell interactions and hydrophilicity, but scaffolds constructed entirely of collagen 
have poor mechanical strength. Therefore, synthetic biodegradable polymers and 
collagen have been hybridized to combine their advantages (Table 1 compares the 
advantages and disadvantages of synthetic and natural scaffold materials ). 
 
 
Table 1. Natural vs synthetic materials used in fabrication of scaffolds11 
 
 Besides the biochemical constituents of the scaffold, the application of 
microfabrication techniques, which allow design and fabrication of so called 
biomimetic surfaces offer interesting options to overcome current limitations128.  
Surface modification can be achieved through; chemically or physically altering the 
atoms or molecules in the existing surface; or coating of the existing surface with a 
material of a different composition. For example, cultured urothelial cells do not grow 
into a confluent layer on PGA or polyglactin mesh because of the large size of the 
mesh interstices. To increase the cell seeding density on the PGA mesh, a method of 
surface hydrolysis has been used to improve the wettability of the mesh129. 
Hybridization of synthetic polymer with collagen has also been used to address these 
problems. Polyglactin 910 mesh and PGA mesh have been coated with collagen 
solution, or embedded in collagen gels, to improve cell attachment and cell seeding.  
In this endeavor to search for a better scaffold for dermal tissue engineering, the 
Department of bioengineering at the National University of Singapore has developed 
a hybrid scaffold using PLGA combined with collagen. In comparison to the 
Dermagraft_ and Invitra CSS™, the other currently available dermal scaffolds, the 
PLGA-collagen scaffold has several advantages. First, the above two products used a 
warp-knitted mesh, whereas the PLGA-c scaffolds are weft-knitted PLGA mesh, 
which has greater 3D volume and has been shown in a separate study to exhibit 
tensile strength and elongation at break that is characteristic of native skin. Secondly, 
collagen has been freeze dried into the PLGA mesh to enhance scaffold 
biocompatibility and to create a microporous network which bridges the large-pore 
spaces within the mesh to enhance cell distribution. To further encourage the 
homogenous distribution and proliferation of HDFs within the scaffolds, PLGA-
collagen mesh was seeded with the use of a novel “cell-sheet” technique. This 
technique improves cell seeding efficiency and also reduces the potential problem of 
pore size causing diminished cell attachment.   
5.7 Cell sheets 
As discussed earlier, signalling molecules and cells required for production of 
biological tissue can be delivered in three ways: as bare protein that is generated 
using recombinant DNA technology, by delivering a gene in a vector that induces a 
cell to produce a protein, or by providing cells that produce the signalling molecules. 
In this experiment, cell-based delivery of signalling molecules was used in the form 
of cell sheets. Besides providing the necessary molecules for production of biological 
tissue, the use of cell sheets have an added advantage when it comes to seeding of 
porous scaffolds used in this study. The method abrogates the issue of cell seeding 
efficiency because those cells that fall to the bottom of the vessel will contribute 
towards the eventual formation of the cell sheet, and therefore are not lost or 
wasted130. The undesirable effects of repeated enzymatic treatment cycles131,132 
carried out in conventional cell expansion protocols will also be circumvented, as 
cells will be allowed to proliferate and mature over a prolonged period of time to 
form neo-tissue. 
Porous scaffolds usually have a drawback of poor cell-seeding efficiency, and many 
methods of generating tissues prove a failure because cells seeded on scaffolds fail to 
attach and proliferate. An effective vehicle for delivery of cells onto these scaffolds is 
therefore imperative if better cell seeding efficiency is desired.  
Fibroblasts and bone marrow cells have been grown into 3-D cell-sheets and 
assembled with knitted scaffolds to engineer tissue. These tissue possess superior 
extracellular matrix (ECM) production and demonstrate encouraging histological and 
mechanical properties. This technique was used to enhance the cell-seeding efficiency 
of the PLGA-c/HDF construct so as to obtain a more ideal dermal substitute with 
better biological and mechanical properties. Significant work has been ongoing 
within the bioengineering department in the National University of Singapore with 
regards to tissue engineering of artificial dermis and dermal replacement strategies. 
This involves the engineering of the dermis with the use of cell sheets. The novel 
technique combining cell sheet and a 3D scaffold was built upon the experience of 
other researchers, who in recent years, have extended the use of cell sheets to produce 
various three-dimensional (3D) neo-tissues. A significant advantage of using cell 
sheets has been the ability to form an entirely natural neo-tissue assembled by the 
cells, with mature extracellular matrix (ECM), thereby enhancing the regenerative 
capacity of the constructs. L’Heureux et al.133 successfully built a tissue-engineered 
blood vessel by wrapping layers of fibroblasts and smooth muscle cells around a 
mandrel. This vessel exhibited well defined three-layered organisation and had a burst 
strength comparable to that of native human vessels. The group also stacked layers of 
fibroblast sheets to form a dermal equivalent, upon which keratinocytes were cultured 
to form a skin equivalent134. Recently, further progress in the culture of cell sheets 
came with the development of culture dishes coated with temperature responsive 
polymers. These culture surfaces become hydrophilic at temperatures below a critical 
point, and hydrophobic at temperatures above the critical point135. As a result, cells 
attach and proliferate on this surface above the critical temperature, and easily detach 
when the temperature is reduced136. It was shown that four layers of cardiomyocytes 
cultured using this technique formed electrically communicative and pulsatile 
myocardial tissue both in vitro and in vivo137.  
Nevertheless, although cell sheets appear physically robust enough to allow careful 
manipulation in a laboratory to produce stacked or wrapped constructs, they contract 
extensively upon detachment from culture surfaces. Thus, it remains a challenge to 
generate a large size tissue of specific shape, using cell sheets techniques alone. 
External supports such as stainless steel rings and polymeric membranes have been 
used to “splint” the developing cell sheet. However, once these supports are removed 
at the point of application, there is resulting loss of size, shape, and even biological 
functions.  
Work at the Department of Bioengineering in the National University of Singapore 
has been to devise a novel technique of cell seeding onto scaffolds to withstand the 
contraction of cell sheets, and eventually apply it for tissue engineering a dermal 
equivalent. It is based on the premise that high density cultures of cells together with 
mechanically stable scaffolds will produce mature cell sheets with the scaffolds 
integrated within them. The cell sheets can then be folded over the scaffolds to form 
3D dermal-like constructs, which will not contract as significantly as pure 3D cell 
sheet constructs. Using this novel approach, a three-dimensional cell sheets is first 
formed before attaching them to the scaffolds so as to enhance tissue regeneration.  
The obvious benefits of assimilating cell sheets with scaffolds include the possibility 
of producing a dermal constructs with mature ECM, which is resistant to contraction. 
It also improves cell seeding efficiency by delivering whole sheets of cells onto the 
scaffold, and the undesirable effects of repeated enzymatic treatment cycles are 
avoided. In addition, keratinocytes can be further cultured on these dermal-like 
constructs to support the regeneration of a bilayered skin equivalent. In a recent study 
by Ng et al130, they evaluated this technique using two scaffolds with the potential to 
be used for dermal regeneration—a weft-knitted poly(lactic-co-glycolic acid) mesh 
with collagen (PLGA-c) like the one used in the current experiment, and a collagen 
sponge cross-linked with hyaluronic acid (CHA). Previous studies have shown that a 
weft-knitted PLGA based mesh was capable of supporting dermal fibroblast 
attachment and proliferation, without contraction15. However, because neo-tissue 
formed was felt to be not as mature and homogeneously distributed as would have 
been desired, the authors used cell sheets in combination with these meshes in an 
attempt to produce a more mature ECM. CHA was chosen as a comparison because it 
was shown to exhibit mechanical stability in terms of greater resistance to enzymatic 
degradation and decreased swelling. It was the first study in which cell sheets were 
cultured together with 3D scaffolds for dermal tissue engineering. Over different 
periods of time, the greatest extent of lateral contraction was observed in HDF-sheet 
controls, with size reductions of 80–90% observed. Contraction of CHA specimens 
was minimal. PLGA-c specimens appeared to have contracted as much as HDF-sheet 
controls. However, instead of a lateral contraction, PLGA-c specimens shrunk as a 
result of curling of the meshes. Cell proliferation and metabolic profiles using 
PicoGreen assay showed that DNA amounts rose equally in all the specimen groups 
from day seven to day fourteen, with no significant differences seen between the 
groups. From day fourteen onwards, DNA amounts in PLGA-c and HDF-sheet 
remained steady while that in CHA continued to increase, significantly exceeding the 
levels recorded in PLGA-c and HDF-sheet (p<0.01). Further culture of the specimens 
revealed that DNA amounts for CHA and HDF-sheet dropped significantly while that 
in PLGA-c remained statistically unchanged (p<0.05). At the end of the study, 
specimen groups were ranked as CHA, PLGA-c, and HDF-sheet in decreasing order 
of total DNA amounts. DNA quantification results corresponded to cell viability 
assessment using confocal laser microscopy images. Viable cells were labeled green 
while nonviable cell nuclei and PLGA threads were labeled red. High cell viability in 
all specimen groups was observed prior to cell sheet encapsulation. Subsequently, a 
general increase in the number of nonviable cells was observed. Results from the 
AlamarBlue™ assay showed similar metabolic activity profiles in all three specimen 
groups. Metabolic activity peaked just prior to detachment of cell sheet, and dropped 
significantly thereafter. Upon seeding of HKs, a rise in metabolic activity was 
recorded. At the end of period three, the metabolic activity of CHA specimens was 
significantly higher than the other two specimen groups. F-actin expression was 
demonstrated in PLGA-c specimens. HDFs expressed defined stress fibers that were 
oriented towards the PLGA threads with cells anchored onto the PLGA and stretched 
outwards to form a cellular network. Stress fibers were also clearly expressed in CHA 
specimens and were oriented according to the alignment of HDFs. Some randomly 
aligned stress fibers were observed in HDF-sheet specimens detached from the 
culture wells. However, these were scattered and poorly expressed due to the loss of 
mechanical support. Histology and immunocytochemistry showed collagen-rich neo-
tissue over the scaffolds, with dense HDF aggregates observed between folded 
interfaces. Neo-tissue aggregates formed above the PLGA-c mesh, similar to that 
seen in HDF-sheet, while thinner neo-tissue layers concentrated on the periphery of 
the CHA scaffold. HDFs infiltrated both the PLGA-c and CHA scaffolds. However, 
the cellular network within CHA was not homogenously distributed. Thin keratin-rich 
layers were detected intermittently on the dorsal surfaces of the constructs. However, 
distribution of keratin-rich layers was not homogenous and did not exhibit the 
complete differentiated strata as in native epidermis. Collagens I and III were 
expressed within the folded cell sheets in all specimen groups but was not present or 
only weakly expressed in the dense HDF aggregates at the folded interfaces, within 
the PLGA-c mesh and within the loose cellular network of the CHA scaffold. 
Cytokeratin-positive keratinocyte layers of less than five cell layers thick were 
evident on the dorsal surfaces of the specimens. Laminin expression was weak and 
not clearly defined between the keratinocyte layers and underlying neo-tissue, 
suggesting only a premature basement membrane organization.  
Representative transmission electron microscopy micrographs presented showed that 
within the PLGA-c meshes, HDFs were well attached onto the PLGA threads. 
Typically, a keratinocyte layer not more than five cell layers thick was observed in 
the specimens. Squamous morphology similar to terminally differentiated 
keratinocytes was observed with desmosomes along cell–cell junctions identified. 
Abundant collagen bundles, but of smaller bundle size compared to native dermis, 
were observed within the folded cell sheet mass in all specimen groups and no 
defined basement membranes were found. 
Growth factor secretion studies indicate TGF-β1 cDNA in all the specimen groups at 
both the time points assessed. KGF cDNA was similarly detected in all the specimens 
except in HDF-sheet. bFGF, TGF-α, VEGF, EGF, and IGF-1 cDNAs were not 
detected at all. TGF-α itself was detected only at the end of the study period, with no 
significant difference between the groups. TGF-α levels in the culture media were 
negligible. TGF- β1 secretion profiles were similar between groups, with recorded 
levels consistently higher than in culture media. In the first period, all specimen 
groups showed TGF-β1 secretion with no significant difference. At the end of the 
second period, TGF-β1 levels gradually dropped and then to an ebb at the end of the 
study period. Secretion of VEGF by all specimen groups was similar, between the 
groups at the start of the culture with mean secretion levels increasing by the end of 
the second period. At the end of the third period, VEGF levels in PLGA-c and HDF-
sheet specimens did not change significantly but surged in CHA specimens. VEGF 
levels in the culture media were negligible. No appreciable amounts of bFGF, EGF, 
and IGF-1 were detected in all specimen groups throughout all time points. 
Therefore, with this novel technique, Ng et al attempts to address the issue of 
extensive contraction associated with the use of cell sheets. This method was used in 
the study to tissue engineer a dermal equivalent and it was shown that the 3D dermal 
equivalents formed using PLGA-c and CHA were viable, metabolically active, 
expressed collagens I and III, and secreted KGF, TGF-β1, and VEGF. 
Conventionally, cell populations are expanded in vitro through repeated cycles of cell 
harvesting via protease treatment, which have undesirable effects on cells. In this 
technique, cells were only subjected to one enzymatic treatment, during cell isolation. 
Isolated cells were then cultured together with a suitable scaffold for a period of time 
that is required to form a cell sheet. The resulting dermal equivalent is thus composed 
entirely of primary cells without any other manipulation. 
By culturing the scaffold in combination with a fibroblast sheet, neo-tissue with more 
matured ECM is achieved, compared to simply culturing fibroblast within the 
scaffold, without cell sheets. This presents both a biological and economical 
advantage over conventional cell expansion techniques 
It was noted that the PLGA-c meshes used in the study curled up during culture in 
contrast to an earlier study in which PLGA-polycaprolactone (PCL) mesh was used. 
This was attributed to several factors. First, dense ECM was not formed in the 
previous study in which cell sheets were not used, resulting in relatively lower 
contractive forces exerted on the scaffolds. Second, the PCL filaments enhanced the 
ability of the previous meshes to resist contraction which the PLGA-c meshes lacked. 
As a result, the contraction of the dense cell sheets on one side of the meshes, coupled 
with the loss of mechanical properties as a result of PLGA degradation, which begins 
after 2 weeks in aqueous environment and completes after 3 months in vivo138, caused 
them to curl up as shown. Therefore, in this current study, a PCL sheet was used to 
envelop the entire construct to partly act as a “splint” to prevent the PLGA-c/cell 
















There appears to be a real possibility of producing prefabricated tissue engineered 
flaps given the current progress in both microsurgery and tissue engineering. 
Naturally, the challenge would be to ascertain the viability and possibility of 
generating complex composite flaps using this model. Clinical trials may then be 
considered should there be consistent and reliable results.  
Specifically, this experiment aims to generate a prefabricated tissue engineered flap in 
vivo by providing vascular supply through an arteriovenous bundle with the 
following parameters evaluated: 
 
1. Document angiogenesis within the scaffold 
2. Evaluate a ligated arteriovenous bundle as a suitable vascular carrier for PLGA 
seeded with HDF. 
3. Document viability and proliferation of seeded cells within the PLGA scaffolds.  
4. To evaluate PLGA-c, enveloped by a cell sheet composed of fibroblasts, as a 




7.1 Scaffold preparation 
The polylactic-co-glycolic acid (PLGA-10/90) fibre was supplied by Shanghai 
Tianqing Biomaterials Company Ltd., Shanghai, China. The PLGA mesh was knitted 
from continuous fibre yarns of PLGA as described. 24 continuous PLGA single fibres 
of 20μm diameter were combined to form a PLGA yarn, which was knitted into a 
mesh using a Silver Reed SK270 Knitting machine. The mesh was folded and fused 
by heat along the edges to prevent fraying. The double-layered mesh was 
approximately 2mm thick. They were stored in a dry cabinet at 17% relative humidity 
prior to use. Rat tail collagen was extracted from fresh animal carcasses and stored in 
lyophilized form until use. The collagen is reconstituted (1.3mg/ml) in 0.05% acetic 
acid and polymerized onto the PLGA meshes by neutralizing with sodium 
bicarbonate (71.2mg/ml) in the ratio of 100:9. PLGA-collagen (PLGA-c) meshes are 
left at room temperature for 30mins for complete polymerization, deep frozen at -
80˚C, and freeze dried overnight. PLGA-collagen were stored in a dry cabinet at 17% 
relative humidity, and sterilized under UV irradiation prior to use. The meshes were 
flexible and highly porous, with loosely bundled fibres not more than 100μm apart. 
Inter yarn spaces ranged from 300-800μm wide. 8mm by 8mm pieces of mesh were 




7.2 Cell culture and cell sheet preparation 
Human dermal fibroblasts (HDF) were derived from human skin samples obtained 
from abdominoplasty, with informed consent.  Epidermis and dermis were separated 
via 5 mg/mL dispase treatment for 16 h at 4°C. The dermis was then disaggregated 
via enzymatic digestion with 2mg/ml collagenase type I (Gibco, Grand island, NY), 
overnight at 37˚, the isolated fibroblasts were subsequently cultured in Dulbecco’s 
Modified Eagle Medium (DMEM, Gibco, NY, USA) supplemented with 10% Fetal 
Bovine Serum (FBS, Hyclone, UT, USA) and 1% Penicillin-Streptomycin (Sigma- 
Aldrich, St. Louis, MO) solution in culture flasks. For routine culture and 
experiments, all cells were maintained in a self sterilizable incubator at 37˚C in 5% 
CO2, 95% air, and 99% relative humidity, with medium changed every 2 days. HDF 
at their 7th passage were used for the entire study. Cell viability assay using 
Fluorescein Diacetate (FDA) (Molecular probes Inc, Oregon) was used. See 
appendices 6.1.7. Pelleted HDF at their 7th passage were resuspended in prewarmed 
PBS containing 5μm of the probe. Cells were then incubated for 15mins at 37˚C. The 
cells were re-pelleted by centrifugation at 1000rpm X 10mins and resuspended in 
complete DMEM. 
The procedure of generating the cell sheet construct is divided into 2 stages. Stage 1, 
the cells were counted with a haemocytometer and static seeded at 100,000 cells onto 
each mesh in 6-well plates (well diameter 35mm). Additionally, HDFs were seeded at 
a density of 50,000per cm2, over the entire well surface. The scaffolds were placed 
centrally within each well and a silicon-coated glass slide was used to weigh down 
each scaffold to the base of the well. The well plates were transferred into the 
incubator and left for 90mins to allow for cell attachment. Each well was then filled 
with 3ml complete DMEM supplemented with 50μg/ml L-ascorbic acid (Sigma, St. 
Louis, USA). The samples were cultured for 10days, with medium change done every 
2 days.  
Stage 2 which coincides with the day of implantation, the confluent HDF sheets were 
mechanically peeled off using fine forceps and folded over the matrices from four 
sides, to form a PLGA-c/HDF construct. Each construct formed one half of the 
“sandwich” scaffold to be implanted.  
 
Fig 5. Each cell sheet was folded over a scaffold from four sides in sequence to obtain a dermal equivalent.(From 
Ng KW et al130 
A total of three pairs of PLGA-c/HDF constructs and two pairs of plain PLGA-c 




7.3 ε-Polycaprolactone film 
These are polyesters related to PLA and PGA with similar biocompatibility, although 
they exhibit a much slower degradation rate. Sutures and drug delivery devices made 
of polycaprolactone and its co-polymers have U.S. FDA approval for many years.   
 Polycaprolactone is synthesized from e-caprolactone as shown below: 
 
Fig. 6 Synthesis of poltcaprolactone from e-caprolactone  
This semi-crystalline polymer absorbed very slowly in vivo by nonenzymatic bulk 
hydrolysis of ester linkages followed by fragmentation and release of oligomeric 
species. ε-hydroxycaproic acid as the sole metabolite. Fragments are ultimately 
scavenged by macrophages and giant cells. Amorphous regions of the polymer are 
degraded prior to breakdown of the crystalline regions. 
Copolymers of e-caprolactone and L-lactide are elastomeric when prepared from 25% 
e-caprolactone, 75% L-lactide and rigid when prepared from 10% e-caprolactone, 
90% L-lactide. 
The interdisciplinary group at the National University of Singapore has developed a 
biaxially stretched  polycaprolactone  film which can be fabricated in a thickness of 
5-15μm139. The ultra-thin film has a novel surface microtexture combined with a high 
tensile strength. The results of studies carried out on this ultra thin film show that they 
support the attachment and proliferation of human epidermal keratinocytes as well as 
fibroblast-like cells140,141.   
7.4 Animal Model 
This study was carried out on 12-16 week nude rats supplied by the Animal Holding 
Unit at the National University of Singapore (NUS). The experiment was carried out 
according to the guidelines issued by the IACUC at NUS with the author undergoing 
the necessary “Responsible care and use of laboratory animals handling course” prior 
to the commencement of the experiments. A total of 5 nude rats of median size 220 
grams (range 190-240grams) were used as experimental animals. The animals were 
housed in the Satellite Animal Holding Unit, located at level 2, MD4, National 
University of Singapore. During the experimental period, the rats were held in 
individually ventilated cages. The animals were fed pelleted diet, and sterile water 
was available ad libitum from bottles.  
8. Methods 
8.1 Cell culture and cell sheet preparation 
See materials 7.2 
8.2 Cell tracer labeling of HDF 
VybrantTM CFDA SE cell tracer kit (V-12883), (Molecular Probes® Inc, Oregon), was 
used to track the HDFs placed within the scaffold (See appendices 13.1.7). The kit 
contains CFDA SE (carboxy-fluoresein diacetate, succinimidyl ester; often called 
CFSE). CFDA SE passively diffuses into cells. It is colourless and nonfluorescent 
until the acetate groups are cleaved by intracellular esterases to yield highly 
fluorescent, amine-reactive carboxyfluorescein succinimidyl ester. The succinimidyl 
ester group reacts with intracellular amines, forming fluorescent conjugates that are 
well retained and can be fixed with aldehyde fixatives. Excess unconjugated reagent 
and by-products passively diffuses into the extracellular medium, where it can be 
washed away. The dye-protein adducts that form in labeled cells are retained by the 
cells throughout development, meiosis and in vivo tracing. The label is inherited by 
daughter cells after cell division, or cell fusion and is not transferred to adjacent cells 
in a population. The approximate excitation and emission peaks of this product after 
hydrolysis are 492nm and 517nm repectively. Cells labeled with CFDA SE can be 
visualized by fluorescence microscopy using standard fluorescein filter sets.  In this 
experiment, pelleted HDFs at their 7th passage were resuspended in prewarmed PBS 
containing 5μm of the probe. Cells were then incubated for 15mins at 37˚C. The cells 
were re-pelleted by centrifugation at 1000rpm X 10mins and resuspended in complete 
DMEM. The cells were incubated for another 30 minutes to ensure complete 
modification of the probe before being used for seeding. 
 
 
8.3 Surgical procedure 
8.3.1 Implantation 
Surgery was performed within the satellite animal holding unit under positive 
pressure hoods. Anaesthesia was achieved with intraperitoneal Hypnorm (Janssen; 
fentanyl citrate 0.315mg/ml; fluanisone 10mg/ml) and midazolam mixture, 2.7ml/kg. 
The rats maintained spontaneous respiration on room air during surgery. Operation 
sites were depilated and washed with betadine directly before surgery, the operating 
sites were disinfected with 70% ethanol and the upper half of the animals was 
covered with a sterile towel. A skin incision parallel to the inguinal ligament on one 
side was made, the fat pad overlying the femoral vessels was reflected off and the 
wound held apart with “fish hook” retracters. Under loupe magnification (2.5X), the 
femoral artery and vein are fully exposed and dissected from the inguinal ligament 
proximally to the origin of the inferior epigastric vessels. Care was taken to preserve 
the adventitia surrounding the vessels. The femoral artery and vein were used as an 
arteriovenous bundle. They were ligated separately and divided between two 8/0 
nylon (Ethilon, Ethicon®, New Jersey) sutures immediately proximal to the origin of 
the inferior epigastric vessels (Fig 7A). The distal end of the vessels were anchored to 
the wound bed to prevent them from retracting more proximally. The PLGA-c/HDF 
constructs were then used to sandwich the arteriovenous bundle. One construct was 
placed below the ligated pedicle and the other over, with the pedicle lying in the 
midline of the constructs and traversing the entire length of both constructs. 
Polycaprolactone(PCL)  film, cut into 1cm X 2cm strips was then wrapped around 
this entire complex to isolate it from surrounding tissue to prevent vascular ingrowth 
from the surrounding tissue (Fig 7B). This is to ensure that the arteriovenous bundle 
remains as the only vascular supply. The PCL envelope was then anchored to the 
upper thigh using 8/0 nylon (Ethilon, Ethicon®, New Jersey) sutures. Control group 
had unseeded PLGA-c mesh sandwiched around the vascular pedicle with a PCL film 
envelope as in the experimental group. The subcutaneous soft tissue was repositioned 
and sutured with 4–0 polyglactin suture (Vicryl, Ethicon®, New Jersey) and the 
superficial layers were sutured back using a continuous technique with the same 4–0 
suture. The animals were then placed in their cages after they were aroused. Health 
condition was monitored during the study period and the operation sites were 
carefully examined daily for two weeks. 4 weeks after implantation, the constructs 
were harvested for analysis. 
 Fig 7A Right inguinal exposure demonstrating the vascular pedicle (paper arrow)at the point of 
ligation immediately proximal to the origin of the inferior epigastric vessels, before truncation. Note 
the fat pad swung up that is supplied by the inferior epigastric vessels.  
 
Fig 7B Construct immediately after implantation. It “sandwiches” the pedicle and is surrounded by 
PCL envelope. 
 8.3.2 Harvest 
Surgery was performed within the satellite animal holding unit under positive 
pressure hoods. Anaesthesia was achieved with intraperitoneal Hypnorm (Janssen; 
fentanyl citrate 0.315mg/ml; fluanisone 10mg/ml) and midazolam mixture, 2.7ml/kg. 
The rats maintained spontaneous respiration on room air during surgery. The 
operating sites were disinfected with 70% ethanol and the upper half of the animals 
was covered with a sterile towel. A skin incision over the previous incision was made, 
the fat pad overlying the femoral vessels was reflected off and the wound held apart 
with “fish hook” retracters. Under loupe magnification (2.5X), the enveloped 
constructs, femoral artery and vein were fully exposed and dissected free. Vessels 
patency was tested prior to ligation of the pedicle using direct compression and 
release along the pedicle with a pair of micro forceps. The proximal end of the 
pedicle was ligated with 8/0 nylon (Ethilon, Ethicon®, New Jersey) sutures and 
transected to obtain the construct attached to the remaining end of the pedicle. The 
animals were then sacrificed by CO2 inhalation. 
8.4 Histology 
For histology, specimens were fixed in 10% buffered formaline, for 24 hours. 
The harvested samples were subsequently placed in labeled plastic cassettes and 
placed in the tissue processor which automatically transfers the cassettes through 
complete dehydration to remove aqueous fixative and any tissue water content, 
'clearing' fluid which is totally miscible with the dehydrating alcohol and finally wax 
embedding agent to impregnate the tissue with molten wax for the final embedding 
stage which sets specimens in blocks of paraffin wax. The blocks are finally cooled 
on an integral cold plate and removed from the mould once the wax is set hard   
Sections are cut from the blocks using a rotary microtome set at 5 microns thickness. 
Cut sections are floated onto a warm water bath to smooth out the creases and then 
lifted out onto a glass microscope slide and allowed to dry on a hot plate set just 
below the melting point of the wax. Once the sections were dried onto the slide they 
were stained.  Sections were stained with haematoxylin-eosin and Masson’s 
Trichrome to demonstrate collagen formation (Appendices 13.1.5 and 13.1.6). 
Stained slides were then mounted under a glass coverslip and viewed under the 
microscope (Olympus IX70). Fluorescence microscopy was also performed using the 
standard fluorescence filters. 
9. Results 
9.1 Gross Morphology 
After four weeks, the implanted scaffolds were examined for external size, 
shape and patency of the pedicle. Both the control (PLGA-c) and PLGA-c/HDF 
constructs showed no significant contraction in size. Their original square shape was 
also maintained (Fig. 9A and 9B). The PLGA-c/HDF constructs appeared uniformly 
thicker and more opaque compared to the unseeded PLGA constructs which remained 
thin and deep blue in colour. The polycaprolactone sheet surrounding the construct 
remained intact with no apparent evidence of extrusion of its contents. All vascular 
pedicles remained pulsatile and bled upon truncation. No significant fibrous capsule 
formation was noted. 
Measurements taken for all 5 pairs of “sandwich” constructs showed that they 
remained unchanged from their preimplantation dimensions of 1cm x 1cm (the size of 
the polycaprolactone envelope) 
  
 
Fig. 8 Construct in-situ just before harvest (After 4 weeks of implantation). Paper arrow shows the 







 Fig. 9A Unseeded PLGA-c construct, immediate pot harvest. Showing the retained morphology of the 
construct with no significant shrinkage or contraction of the construct after 4 weeks of implantation. 
 
 
Fig. 9B Seeded PLGA-c construct, immediate post harvest. Morphology is maintained with no 
significant shrinkage. 
9.2 Cell Tracer activity 
Cell tracer studies showed that the labeled HDFs that were used to seed the PLGA-c 
scaffolds at the start of the experiment remained viable and were adjacent to the 
remaining scaffolds as evident by their fluorescence (Fig 10A and 10B). 
Qualitatively, viable cells were seen in all the seeded specimens as green fluorescent 
bodies.  The green fluorescent bodies were typically seen closely associated to 
remnant PLGA-c fibres (Fig 11A and 11B). Few fluorescent bodies were noted 
within the cellular interyarn spaces. This is due to gradual loss of the fluorescent  









Fig 10A and 10B. viewed under normal light and fluorescence microscopy, respectively (Olympus IX 
70). These two representative images are taken of the same slide at 10X magnification, with and 
without fluorescent filter. Fluorescence is seen in image 7B as evident by the green specks. The site 
corresponds to the PLGA-c fibres. 
  
 
Fig. 11A and 11B Higher magnification (40X) view of another slide showing more clearly the 
association between fluorescent cells and PLGA-c fibres. Note the bluish material over the bottom half 
of fig. 8A. This corresponds to where fluorescent cells are seen in fig 8B.  
 
9.3 Histological Analysis 
At low magnification (10X), the PLGA-c/HDF constructs showed a relatively 
homogeneous distribution of cellular tissue (Fig 12B). There was good penetration of 
neo-tissue throughout the full thickness of the scaffold with no conglomerates of cells 
forming within the construct. Plain PLGA-c scaffolds had scanty cellular deposits 
within the inter-yarn spaces with distinct blue coloured remnant PLGA-c fibres seen 
(Fig 12A). Under higher magnification (40X), most of the seeded PLGA-c fibres 
were surrounded by neo-tissue and had a greater number of cells per high powered 
field compared to the controls (Chart 1).  
 





















Fig 12. Mean cell count, 3 high powered fields (hpfs) per slide, using 4 different sections. C1: control 
1, unseeded PLGA-c construct; C2: control 2, unsseded PLGA-c construct; S1: specimen 1, PLGA-




PLGA-c fibres seeded with HDF appeared to undergo greater degradation compared 
to controls as evident by the decreased number of PLGA-c fibres (Fig 13B). There 
appeared to be no obvious foreign body reaction or inflammation within the seeded 
scaffolds. Plain PLGA-c constructs consisted mainly of PLGA-c fibres with little 
tissue formation or cells in between the fibres (Fig 13A). The PLGA-c fibres 
remained largely intact with no evidence of inflammation or foreign-body reaction. 
Chart 2 shows the mean number of PLGA-c fibres left intact in control and seeded 
constructs.  
 
























Fig. 13 Mean number of intact PLGA-c fibres, 3 high powered fields (hpfs) per slide, using 4 different 
sections. C1: control 1, unseeded PLGA-c construct; C2: control 2, unsseded PLGA-c construct; S1: 
specimen 1, PLGA-c/cell sheet construct; S2: specimen 2, PLGA-c/cell sheet construct; S3: specimen 





Fig. 14A H and E slide (10X) of a representative control slide showing obvious PLGA-c fibres with 
their typical ovoid cross sections closely poacked together with scant interyarn cellular material. Note 
also the well encapsulated construct with no breach of tissue through the e-polycaprolactone film 
(bottom right of slide). The vascular pedicle is well seen on this slide with the more muscular artery 
next to the thin walled, red blood cell filled, vein. 
 Fig 14B. H and E of a PLGA-c/cell sheet construct (10X) showing much less remnant PLGA-c fibres 
and larger amounts of cellular material almost homogenously distributed throughout the sample. Again 








Fig. 15A H and E slide of a representative control specimen at high power (40X) showing mainly of 
PLGA-c fibres with little tissue formation or cells in between the fibres. The PLGA-c fibres remained 
largely intact with no evidence of inflammation or foreign-body reaction. Note the closely packed and 
relatively well preserved PLGA-c fibres seen in their cross sections. 
 
 Fig. 15B . H and E of a PLGA-c/cell sheet construct (40X) showing much less remnant PLGA-c fibres 
and larger amounts of cellular material almost homogenously distributed throughout the sample. In 









 Capillary structures were noted throughout both the seeded and unseeded 
PLGA-c constructs with no obvious extrinsic ingrowth of vessels from tissue outside 
of the PCL envelope.  
Under high power magnification, angiogenesis was also evident in both the 
control and PLGA-c/HDF constructs. No obvious difference in number of capillaries 
within plain PLGA-c constructs and PLGA-c/cell sheet constructs were noted (Chart 
3). Neo-capillaries were seen sprouting from the lumen of the femoral vein (Fig 14). 
These capillaries were noted within the inter-yarn spaces and neo-tissue of both the 
PLGA-c/HDF as well as the control constructs. New capillaries were also found 
away from the arteriovenous bundle, right to the edge of the constructs (Fig 15). No 
apparent vessel ingrowth from surrounding tissue was noted to traverse the e-
polycaprolactone film. The e-polycaprolactone film used to isolated the construct 
from surrounding tissue maintained a distinct barrier between the contents of the 
envelope and the surrounding tissue. No new capillaries were seen sprouting from the 
arterial side of the pedicle. 

























Fig 16. Mean number of capillaries counted over 3 high powered fields (hpfs) per slide, using 4 
different sections. C1: control 1, unseeded PLGA-c construct; C2: control 2, unsseded PLGA-c 
construct; S1: specimen 1, PLGA-c/cell sheet construct; S2: specimen 2, PLGA-c/cell sheet construct; 
S3: specimen 1, PLGA-c/cell sheet construct 
 
 Fig 17 Seeded PLGA-c construct at high power (40X H and E) showing luminal sprouting from the 
venous lumen. Similar sprouting was noted in control constructs from the venous lumen. 
 Fig. 18 Control construct (H and E, 40X) showing capillaries within the construct. These capillaries 
were found throughout seeded and unseeded constructs. Note that capillaries were also seen upto the 
edge of the constructs which had been isolated by e-polycaprolactone film from surrounding tissue and 








Masson Trichrome stains of the seeded PLGA-c scaffolds and control 
specimens, demonstrated greater amount of collagen formation in the HDF seeded 
constructs compared to the unseeded constructs (Fig 16A and 16B). More collagen 
fibres were noted on high power magnification (40X) in the PLGA-c/HDF scaffolds 
compared to plain PLGA-c scaffolds. Collagen fibres seen within the control PLGA-c 
scaffolds were closely associated with the walls of the ingrowing capillaries and 
vessels (Fig 17A). Collagen fibres seen within the PLGA-c/HDF scaffolds  were seen 
within the inter-yarn spaces, between the cellular neo-tissue as well as the ingrowing 






 Fig 19A Masson’s Trichrome (10X) of control specimen showing scant collagen formation 
concentrated mainly around the vascular pedicle. 
 
Fig 19B Masson’s Trichrome (10X) of seeded specimen showing collagen fibres stained blue-green 
throughout the construct. 
 Fig. 20A At higher power (40X, Masson’s Trichrome). Collagen fibres are noted mainly along the 




Fig. 20B Seeded PLGA-c construct at higher power (Masson’s Trichrome). Collagen fibres are seen 
throughout the construct and inter-yarn spaces. The collagen fibres were not confined to the capillaries. 
10. Discussion 
Over the years we have evolved from just filling a defect to replacing like for like for 
tissue and functional reconstruction. With improvement in microsurgical techniques, 
prefabrication of flaps for use at a distant site has become a reality. Tissue 
engineering provides a prospect of generating tissue to replace or restore defects that 
result from surgical extirpation, disease or congenital anomaly. It allows us to 
alleviate the problem associated with lack of suitable autologous tissue or donor site 
morbidity. Nevertheless, tissue engineered constructs are often limited by their 
intrinsic lack of blood supply. Most constructs rely either on surrounding tissue for 
blood supply or are avascular. Following recent work that suggests that an isolated 
vascular supply, both in the form of a pedicle or an arterio-venous loop, can support 
neo-tissue development and allow microvascular transfer of these generated tissues. It 
is a natural extension therefore, to try to combine a dermal substitute with a vascular 
supply such that a potentially transferable tissue engineered prefabricated flap is 
produced. This experiment utilizes various tissue engineering techniques together 
with flap prefabrication techniques to attempt to produce a tissue engineered 
prefabricated vascularised flap and a discussion based on the above results is made 
here. 
10.1 Vascular Supply and Angiogenesis 
The use of free tissue transfer has expanded greatly over the past three decades, and 
there are now a large number of flaps available for reconstruction. Despite these 
surgical advances, there is still a paucity of thin flaps and flaps that match recipient 
site colour and texture. This is especially so in head and neck reconstruction where 
aesthetic outcome must also meet functional requirements.  Emphasis has shifted 
from simply flap survival to better flap selection to obtain like-for-like tissue, 
minimizing donor site morbidity and refinement in reconstruction. Flap prefabrication 
is one method of creating a custom-made flap that meets the specific requirements of 
a given recipient site. It requires a donor blood supply and a donor site for the blood 
supply to be implanted, to allow for flap maturation before transfer of the 
prefabricated flap. In this experiment, the femoral artery and vein was used as the 
vascular pedicle and the prefabricated scaffolds were used as the “donor site”. The 
results suggest that the femoral artery and vein can serve as the angiogenic source for 
the tissue engineered construct as evident by the capillary outsprouting that occurred 
almost exclusively from the venous side of the pedicle. This and because of its 
relative ease of dissection, makes it an ideal pedicle for subsequent evaluation of 
other constructs of different material or design. Furthermore, because its length may 
be extended if need be to the level of the knee joint, a relatively long pedicle may be 
achieved. None of the five pedicles were thrombosed at the end of the experiment 
which further demonstrates the reliability of this pedicle. This is a significant benefit 
because future studies would require microvascular transfer of the prefabricated flap 
in which patent donor and recipient vessels would be an implicit prerequisite. A 
ligated pedicle would serve as a very useful vascular supply to these prefabricated 
constructs clinically because of its reliability and the relatively short operative time 
required to fashion them.  
Viability of prefabricated flaps depends on angiogenseis and neovascularization 
occurring within the flap. Our current knowledge of angiogenesis and 
neovascularization in flaps is based mainly on conventional free flaps and 
prefabricated flaps. Little is known on angiogenesis and neovascularization of tissue 
engineered “flaps” (this term is used very loosely, as the tissue engineered construct 
is strictly not a flap by current definition). Many factors influence vascularization of 
prefabricated flaps and has been postulated to occur through one of three processes. 
The first process is inosculation where capillaries of the recipient bed and those of the 
flap join together to reestablish antegrade flow. This mechanism was not applicable in 
our study as there is no recipient bed of blood vessels to speak off and hence rapid 
establishment of antegrade blood flow is not achievable. The other two processes are 
subtypes of neovascularization. Neovascularization can originate from capillary 
sprouting from preexisting vessels within a flap increasing absolute number of vessels 
in a given area. Alternatively, recipient-bed vessels can grow into the flap. The 
difference between the two being that the “mother” vessels are of different origins, 
one indigenous to the flap, the other indigenous to the recipient bed. The results from 
this experiment seem to suggest that capillaries have grown into the tissue engineered 
construct without the need for pre-existing vessels within the construct and hence it is 
reasonable to conclude that the “mother” vessels in this tissue engineered 
prefabricated flap is entirely from the femoral vessels. Even though in this experiment 
the tissue engineered flaps were not raised and transferred to a distant site, it is a 
reasonable conclusion in view of the cell tracer activity within the isolated constructs 
to conclude that neovascularization originating from the pedicle alone was sufficient 
to maintain viability of the cells within the construct without the other two 
mechanisms of vascularization coming into play.  
Angiogenesis and neovascularization are likely a continuum of the same biologic 
process that may be fostered in the local environment by angiogenic factors such as 
platelet-derived growth factor, tumour growth factor, and basic fibroblast growth 
factor or by regional factors such as global or distal ischaemia. The most likely source 
of angiogenic factors in the formation of a prefabricated flap are endothelial cells or 
macrophages within the inflammatory reaction provoked by pedicle implantation or 
flap elevation. The specific biologic factors involved in the vascularization of the 
tissue engineered constructs were not studied but it is postulated that the 
inflammatory reaction from pedicle implantation alone provided sufficient stimulus 
for angiogenesis to occur. Seeded scaffolds with the cell sheet envelop did not appear 
to result in greater neovascularization which is somewhat surprising for two reasons. 
The additional cells in the seeded scaffolds would have experienced relative hypoxia  
upon implantation. This would have resulted in greater production of hypoxic 
byproducts and even cell death with resultant biochemical e.g pH and inflammatory 
responses which should have shifted the balance in favour of angiogenesis. 
Furthermore, with biologically active cells within the milieu of the pedicle, one would 
have suspected a more noticeable paracrine response toward angiogenesis by the 
HDFs. Nevertheless, the small sample size and transient nature of some of the 
biochemical and inflammatory responses might have left liitle impact on the 
neovascularization noted at the end of 4 weeks. Future studies might focus on actual 
quantification of some of these factors over different time intervals. 
The mode of placement of the pedicle is of crucial importance. Studies on 
prefabricated flaps confirm that placing the pedicle immediately beneath the dermis 
and ensuring the whole length of the pedicle remains in close apposition with the 
dermis, coupled with special care to ensure that the pedicle lies in the center of the 
proposed flap provides the most ideal result. This observation was applied in this 
study in that the pedicle was placed in the middle of the constructs and secured 
distally to minimize retraction of the pedicle. It is notable that the tissue engineered 
construct seemed to behave in a similar pattern to a cellular dermis in terms of its 
response to neovascularisation, allowing capillary outsprouting to reach even the 
most distal portions of the flap.    
It is well known that other investigators have attempted to improve flap survival by 
introducing growth and angiogenic factors. This occurred mainly in experiments 
involving prefabricated flaps as opposed to tissue engineered prefabricated flaps, and 
as this was an initial in vivo study on this particular novel dermal substitute, growth 
factor augmentation and other biochemical techniques of improving flap viability was 
not studied so as to minimize confounding factors to our results. 
 
10.2 PLGA-c, cell sheet construct    
The ideal scaffold is one that should be non-toxic, nonantigenic, noncarcinogenic, 
nonteratogenic, and possess high tissue biocompatibility. This is over and above its 
other physical like the macrostructure, porosity and pore interconnectivity, pore size, 
surface area, surface chemistry, and mechanical properties, which has to be optimized 
and matched to the tissue being replaced/regenerated. Scaffolds are necessary for 
providing tissue morphology and delivering signalling molecules in the form of 
proteins, cells or genes. These implantable biomaterials derived from either naturally 
occurring tissues (e.g. collagen, hyaluronic acid, demineralized bone matrix, acellular 
dermis, small intestinal mucosa), polymers ( polyglycolic acid, polylactic acid, 
polypropylene fumarate), or metal ( titanium finre mesh) can be modified by binding 
peptides to the surface to enhance biomolecular recognition by the cells. These 
biomimetic scaffolds are currently being developed and this study served partly to 
evaluate the invivo characteristics of this novel construct described by Ng et al130.  
In the prefabrication of a tissue engineered soft tissue flap, a scaffold that is capable 
of supporting the development of dermal-like neo tissue is required. The scaffold 
should also be pliable, allow custom design, encourage the homogenous proliferation 
of cells and yet be able to withstand cell contraction forces. Previous in vitro studies 
have demonstrated that PLGA has properties that allows relatively homogenous 
distribution and proliferation of cells within the inter yarn spaces compared to 
Alloderm®. Furthermore, contraction and distortion of PLGA was minimal compared 
to TissuFleece®. In this in-vivo model, gross morphology of the harvested 
prefabricated tissue engineered flaps suggest that the constructs seeded with HDFs 
were thicker which reflects the greater quantity of cellular proliferation and 
extracellular matrix production compared to unseeded scaffolds. This was also 
evident on histology where greater cell counts and collagen production was noted 
within the PLGA-c/HDF scaffolds. The PLGA-c fibres therefore served as suitable 
scaffold for the continued survival and proliferation of human dermal fibroblasts 
(HDFs) and these fibroblasts that proliferated within the construct were able to induce 
more collagen production than the unseeded PLGA-c constructs. The HDFs were also 
generally homogenously distributed within the construct with high cell counts per 
high powered field compared to unseeded scaffolds. Continued proliferation and 
survival of HDFs in PLGA-c scaffold makes it a suitable cell carrier and model for a 
resorbable scaffold that would be replaced by proliferating autologous cells. Thus, 
this in vivo study further corroborates previous in vitro work done on PLGA-c/HDF 
scaffolds to show that cell sheet technology is an effective vehicle for cell delivery 
onto a porous scaffold.   
Results after 4 weeks of implantation also showed that the PLGA-c/HDF and plain 
PLGA-c constructs maintained their original shape and size regardless of whether 
they were seeded with HDF or not. Effects of capsular contraction was avoided 
possibly due to the duration of implantation (more extensive contraction might have 
been seen if implantation was for a longer duration), and the “splinting” effect of the 
polycaprolactone film that was used to isolate the construct from the surrounding 
tissue. This quality is crucial for prefabricated flaps as contraction and distortion 
would lead to loss of definition, scarring and contracture. Herein lies one of the 
greatest advantage of incorporating synthetic materials within scaffolds, which allows 
the possibility of using various processing techniques to fabricate matrices of desired 
form, mechanical strength and degradation profiles to achieve specific tissue 
engineering goals. The scaffold in this study was able to resist contraction forces of 
both the seeded cells within the scaffold as well as cells surrounding the construct. 
The “knitted” quality of the material also allows the scaffold to be folded and shaped 
into various designs relatively easily. This would enable the scaffold to fit various 
shapes, contours and designs if so required. This generated construct may therefore 
potentially serve as a prefabricated “flap”. 
Combining cell sheets with scaffolds therefore harnesses the strengths of cell sheet 
tissue engineering and synthetic biomaterials. This technique can overcome the issue 
of extensive contraction when using cell sheets alone, it capitalizes on the mechanical 
strength of the synthetic scaffold and the “splinting” effect of the PCL envelope, yet 
avoid the less than optimum biological characteristics of pure synthetic scaffolds.  
 
11. Conclusion 
This technique can be used to tissue engineer a soft tissue “flap” of specific shape and 
size. This tissue engineered flap would require little intrinsic tissue and hence 
minimal donor site morbidity. It shows that a ligated pedicle is a suitable model for 
providing a vascular supply to an otherwise avascular cellular construct. The PLGA-
c/cell sheet constructs appear to be as a suitable scaffolds for a prefabricated flaps 
with homogenous distribution of cells within the construct that remain viable after 4 
weeks. Minimal distortion of the constructs were also noted at the end of 4 weeks. 
Vascularisation of prefabricated flaps would eventually allow for larger and more 
complex constructs and allow these vascularised constructs  to be transfered to a 
distant site. This has wider implications for tissue engineering and transplantation in 
general as it addresses the core limitations of transplantation and tissue engineering42 , 
which are immune rejection and nutrient blood supply. 
Clinically, this technique might offer new avenues for autologous, scaffold-based 
tissue engineered prefabrication of flaps. Current in vitro studies in our laboratory 
have seen some success in adding an epithelial layer over the dermal construct and 
further studies in an in vitro model will hopefully lead to the development of a more 
complex soft tissue flap. Applications for gene therapy have also been recently 
described for tissue engineered scaffolds seeded with transfected plasmids142. There 
fore, it would not be too difficult to imagine a vascularised flap being used to deliver 
gene therapy in future.  Further studies should assess the molecular markers involved 
in angiogenesis and cell proliferation within this tissue engineered flap and the 
performance of this construct in a immunocompetent model as capsular formation 
and inflammation may affect results. 
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13.1 Laboratory Protocols in Detail 
13.1.1 Tissue Processing 
 
Before any microscopic examination can be done on a piece on a piece of tissue, it 
has to undergo tissue processing. Tissue processing is the treatment that allows 
paraffin impregnation.  
 
When a biopsy is taken from a patient, it must be fixed. Fixation preserves cells and 
tissue constituents in a condition identical to that existing during life. It also allows 
tissues to remain unchanged by subsequent treatment. Fixation should be performed 
immediately since delay permits autolysis and drying. 10% neutral buffered neutral 
formalin is considered the best general fixative.  
 
After fixation, the tissues undergo dehydration, clearing and infiltration – the three 
stages of tissue processing. The purpose of these sequential steps is to remove the 
extractable water from tissue specimens and replace it with a medium that solidifies 
(e.g. paraffin wax) to allow sectioning. Alcohols- isopropyl or ethyl- are the usual 
choice for dehydration to remove the fixative and water from the tissue. Xylene is 
routinely used to replace the dehydrating fluid with a fluid that is totally miscible with 
both the dehydrating fluid and the embedding medium, paraffin wax.  
 
After complete impregnation with wax, it is necessary to obtain a solid block 
containing the tissue by the process of embedding. This is achieved by filling a mould 
of suitable size with molten wax, orientating the specimen in the mould to ensure it is 
being cut in the right plane and cooling the mass to promote solidification.  
 Embedding is usually done in an embedding center. An embedding center comprises 
of 3 main compartments: 
 
• Wax dispenser: automatically dispensed appropriate amount of wax into 
cassette. 
• Cold plate: allow the wax at the base of the mould to semi-congeal for easy 
orientation of tissue and also to cool the paraffin wax quickly. 
• Heated storage area for moulds: to maintain wax in liquid state so that bacteria 
do not grow. 
 
13.1.2 Tissue Processing Schedule 
 
Automatic tissue processors enhance the processing of tissues by using heat, vacuum, 
pressure and agitation.  
 
 
Table 3. Tissue processing schedule 
 
 
Bath Reagent Routine Processing Schedule 
Short Schedule for 
Biopsies 
1 10% Formalin 2 Hr 30 min 
2 70% Alcohol 1 Hr 15 min 
3 95% Alcohol I 1 Hr 15 min 
4 95% Alcohol II 1 Hr 15 min 
5 Absolute Alcohol I 1 Hr 15 min 
6 Absolute Alcohol II 1 Hr 15 min 
7 Absolute Alcohol III 1 Hr 15 min 
8 Xylene I 1 Hr 15 min 
9 Xylene II 1 Hr 15 min 
10 Xylene III 1 Hr 15 min 
11 Paraffin I 2 Hrs 45 min 
12 Paraffin II 2 Hrs 45 min 
Total:  15 Hrs 4 Hrs 15 min 
 
13.1.3 Paraffin Embedding Protocol 
 
1. Transfer the cassettes containing the dehydrated and infiltrated tissues from the 
tissue processor into the cassette bath. 
2. Open a processing cassette in order to view the tissue sample and orientate the 
tissue as desired.  
Note: Discard the lid of the embedding cassette. 
3. Select a mould that best corresponds to the size of tissue and place it under the 
dispenser outlet nozzle.  
4. Partly fill the mould with paraffin and transfer to the refrigeration unit.  
5. With a warm forceps, transfer the previously orientated tissue, place it at the 
bottom of the mould and press gently to hold the tissue in place. 
Note: The above must be carried out rapidly to avoid a film to form on the surface of 
the paraffin. Otherwise, this would create two phases in the finished block leading to 
fissures, which subsequently may cause the block to break during sectioning. 
6. Place the cassette base above the mould and fill to brim with paraffin. 
7. Transfer the mould carefully to the cold plate. The paraffin should solidify in 
about 15-30 minutes, after which the paraffin block can be easily removed from 




13.1.4  Microtomy 
 
Tissue can be sectioned, attached to a surface and examined under a microscope. 




Before sectioning a block, examine it and establish how it should be oriented in the 
block holder. Set the thickness setting to about 15μm and trim the block till the entire 
surface of tissue is exposed. The tissue block is then placed on cooler or into ice 




Set the thickness setting to about 3-5 μm. The hand wheel should be turned at a slow 
and even speed to produce a long ribbon of sections of even thickness. Interrupted 




A camel’s hair brush, a fine-eyed forceps or a dissecting needle may be used to 
handle the ribbon as it comes out of the microtome knife. Float the ribbon into a bath 
of 20% alcohol prior to floating it on the warm water bath, which is set at about 47 ºC 
to 51ºC. The ribbon is then gradually lowered onto the water bath to eliminate 
wrinkles and entrapped air. Allow the sections to remain on the water bath until they 
are flattened. The sections are separated and placed onto cleaned pre-labelled 
polylysine slides. 
 
13.1.4.4 Draining and Drying of Slides 
 
The slides are then drained vertically, failure of which may result in the presence of 
bubbles under the tissue and the subsequent decrease in tissue adhesion to the slides. 
Air bubbles also produce section unevenness and staining artefacts. After draining, 
the slides could either be placed on a warming table or oven that is set at 37ºC to 
40ºC where they are to remain overnight. (Note: For immunohistochemistry 
procedures, drying will have to be overnight at 37ºC to prevent destroying antigens). 
13.1.5 Hematoxylin and Eosin (H&E) 
 
 
Hematoxylin is the most widely used natural dye in histotechnology and is commonly 
employed as a nuclear dye in the standard H&E, the primary staining method or 
tissue section analysis. 
 
Hematoxylin is extracted from the heartwood of a South American tree Haematoxylin 
campechianum. Hematoxylin itself is not a dye, rather the oxidized product of 
hematoxylin – the haematein is considered the dye. Haematin is an anionic 
compound; it will not directly stain tissues but needs a mordant provided by metal 
cation such as iron or aluminium. Hematoxylin, being a basic dye, has an affinity for 
the nucleic acids of the cell nucleus. 
Hematoxylin stains are either “regressive” or “progressive”. With a regressive stain, 
all tissue structures are stained and thus require a controlled decolourisation and 
“bluing” steps to arrive at the optimum nuclear staining results. A progressive 
procedure stains the nuclei only. An example would be the Gills’ III hematoxylin 
which is used in the author’s laboratory. 
 
Eosin is an acidic dye with an affinity for cytoplasmic components of the cell. 
Proteins are generally cationic below pH 6 and will thus bind to eosin. The most 
frequently used form is eosin Y that gives yellowish-pink shades and be prepared as 
either an alcoholic or aqueous solution.  
 
13.1.5.1 Procedure for Hematoxylin & Eosin (H&E) Staining 
1. De-paraffinize slides in 3 changes of xylene  
2. Hydrate the slides through the series of graded alcohols (absolute to 95% to 70% 
alcohols) before bringing the slides to water. 
3. Stain the slides in freshly filtered Gills’ III Hematoxylin for 2-5 minutes, 
depending on the intensity desired. 
Note: Gills’ III Hematoxylin is a progressive hematoxylin stain, which only stains the 
nucleus. Thus, controlled decolourisation in acid alcohol not required unlike in the 
regressive hematoxylin stain procedures. 
4. Wash in running tap water briefly. 
5. Give the slides a single dip in the ammonium hydroxide bath until sections turn 
“blue”. 
6. Wash briefly in tap water. 
7. Stain the slides in eosin for 1-2 minutes. 
8. Dehydrate the slides through the series of graded alcohols (70% to 95% to 
absolute alcohols). 
Note: Leave the slides longer in the absolute alcohols baths to completely dehydrate 
the slides since any presence of water droplets may result in the presence of water 
droplets on the sections even after mounting. 
9. Clear the sections in 3 changes of xylene. 
10. Mount the sections in DPX. 
 Results 
Nuclei ……………………………………………….. Blue 
Cytoplasm …………………………………………… Pink to Red 
Most other tissue structures ………………………….. Pink to red 
 
13.1.6 Masson’s Trichrome 
 
This method is used for the detection of collagen fibers in tissues such as skin, heart, 
etc. on formalin-fixed, paraffin-embedded sections, and may be used for frozen 
sections as well. The collagen fibers will be stained blue and the nuclei will be stained 
black and the background is stained red. 
 
13.1.6.1 Reagents 
Iron Hematoxylin Solution:  
      Stock Solution A:  
      Hematoxylin ----------------------------- 1 g  
      95% Alcohol ----------------------------- 100 ml  
      Stock Solution B: 
      29% Ferric chloride in water --------- 4 ml  
      Distilled water ----------------------------- 95 ml  
      Hydrochloric acid, concentrated ---- 1ml  
      Iron Hematoxylin Working Solution:  
      Mix equal parts of stock solution A and B. This working solution is stable for 3 
months. 
Biebrich Scarlet-Acid Fuchsin Solution: 
      Biebrich scarlet, 1% aqueous --------- 90 ml  
      Acid fuchsin, 1% aqueous --------------10 ml  
      Acetic acid, glacial ------------------------ 1 ml  
   
Phosphomolybdic-Phosphotungstic Acid Solution: 
      5% Phosphomolybdic acid ------------- 25 ml  
      5% Phosphotungstic acid --------------- 25 ml  
Aniline Blue Solution: 
      Aniline blue --------------------------------- 2.5 g  
      Acetic acid, glacial --------------------- 2 ml  
      Distilled water ----------------------------- 100 ml  
   
1% Acetic Acid Solution:  
      Acetic acid, glacial ----------------------- 1 ml  
      Distilled water ------------------------------ 99 ml  
 
13.1.6.2  Procedure for Masoon’s Trichrome staining 
1. Deparaffinize slides in 3 changes of xylene  
2. Hydrate the slides through the series of graded alcohols (absolute to 95% to 70% 
alcohols) before bringing the slides to water  
3. Mordant in Bouin's Solution at room temperature overnight in a hood.  
 
Note: Be careful, Bouin's solution is hazardous and the picric acid, when in less than 
10% water, is very explosive. Used Bouin's solution should be placed in an 
appropriate waste container. 
** Bouin's Solution intensifies the final coloration of the tissue. 
4. Wash slides in running tap water to remove yellow color from sections. Rinse 
briefly in distilled water. 
5. Stain in Working Iron Hematoxylin Solution for 5 minutes.  
Note: Make Hematoxylin Solution fresh by adding equal volumes of Solution A (1% 
Hematoxylin in 95% EtOH) and Solution B (1.2% Ferric Chloride and 1% Acetic 
Acid in distilled water). The working solution is good for approximately 10 days. 
** Hematoxylin stains nuclei blue-black. 
6. Wash in running tap water for 5 minutes. Rinse in deionized water. 
7. Stain in Biebrich Scarlet-Acid Fuchsin for 5 minutes. 
Note: Decreased red staining usually indicates that the staining solution has aged or 
been overused and should be discarded. 
** Beibrich scarlet-acid fuchsin stains cytoplasm and muscle red. 
8. Rinse in deionized/distilled water. 
9. Place the slides in Phosphomolybdic/Phosphotungstic Acid Solution for 5-10 
minutes.  
Note: Freshly prepare Working Phosphotungstic/Phosphomolybdic Acid Solution by 
mixing 1 volume of Phosphotungstic Acid Solution and 1 volume of 
Phosphomolybdic Acid Solution with 2 volumes of distilled water. Discard after one 
use. Formation of a precipitate in Phosphomolybdic Acid Solution does not affect 
performance. 
** This allows for uptake of the aniline blue stain. 
10. Stain sections in Aniline Blue Solution for 5 minutes. 
**Aniline blue stains collagen blue. 
11. Rinse slides briefly in distilled water. 
12. Place slides in 1% acetic acid solution for 3-5 minutes.  
Note: Rinsing in acetic acid after staining renders the shades of color more delicate 
and transparent. If blue staining of connective tissue appears faded, the section has 
probably been over differentiated in the acetic acid solution. 
13. Dehydrate to xylene. 
14. Leave slides in xylene overnight to get good clearing of the ethanol. 
15. Coverslip slides using Permount or Polymount (xylene based). 
Note: Place a drop of Permount on the slide using the glass rod, taking care to leave 
no bubbles. Avoid stirring the Permount with the rod too much and make sure that 
xylenes still cover the slide.Angle the coverslip and let fall gently onto the slide. 
Allow the Permount to spread beneath the coverslip, covering all the tissue. 
16. Dry overnight in the hood or at 37°C. 
 
Results:    
      Collagen --------------------------------------------- blue  
      Nuclei ------------------------------------------------- black  
      Muscle, cytoplasm, keratin ------------------- red    
Positive Controls: 
      Skin, lung, stomach, intestine. 
 
 
13.1.7 Cell tracer labeling 
The VybrantTM CFDA SE Cell Tracer Kit ( V-12883) as the cell tracing reagent. It 
provides a versatile and well retained cell-tracing reagent in a convenient and easy-to-
use form. The kit contains  CFDA SE ( carboxy-fluorescein diacetate, succinimidyl 
ester; often called CFSE) in ten single-use vials. Small-scale experiments can be 
performed without preparing excess quantities of perishable CFDA SE stock solution.  
 
Fig. 21. Mechanism of cellular labeling by CFDA, SE. CFDA, SE is a nonpolar molecule that spontaneously penetrates cell 
membranes and is converted to anionic CFSE by intracellular esterases. Amine-reactive coupling of CFSE to proteins results in 
stable long-term intracellular retention. 
 
CFDA SE passively diffuses into cells. It is colourless and nonfluorescent until its 
acetate groups are cleaved by intracellular esterases to yield highly fluorescent, 
amine-reactive carboxyfluorescein succinimidyl ester. The succinimidylester group 
reacts with intracellular amines, forming fluorescent conjugates that are well-retained 
and can be fixed with aldehyde fixatives. Excess unconjugated reagent and by 
products passively diffuses to the extracellular medium, where it can be washed 
away.  
The dye protein adducts that form in labeled cells are retained by cells throughout 
development, meiosis and in vitro tracing143.  The label in inherited by daughter cells 
after cell division or cell fusion, and is not transferred to adjacent cells in a 
population144,145,146. Lymphocytes labeled with CFDA SE have been detected up to 
eight weeks after injection into mice in lymphocyte migration studies147, and viable 
hepatocytes that are similarly labeled were easily located by fluorescence microscopy 
even 20 days after intrahepatic transplantation148. 
13.1.7.1 Reagent preparation 
Prepare a 10mM CFDA SE stock solution immediately prior to use by dissolving the 
contents of one vial (Component A) in 90μL of the DMSO provided (Component B). 
Dilute the stock solution in phosphate-buffered saline (PBS) or other suitable buffer 
to the desired working concentration (0.5-25 μM). 
13.1.7.2 Labeling of cells 
1. Grow cells inside a suitable culture vessel with appropriate culture medium 
2. When cell have reached the desired density, remove the medium from the dish 
and add prewarmed (37°C) PBS containing the probe. 
Note: The concentration of probe for optimal staining will vary depending upon 
the application; manufacturer’s recommendation is to test at least a ten-fold range 
of concentrations. In general, long term staining (more than about three days) or 
the use of rapidly dividing cells  will require 5-10 μM dye. 
3. Incubate the cells for 15min at 37°C 
4. Replace the loading solution with fresh, prewarmed medium and incubate the 
cultures for another 30minutes at 37 °C. During this time, CFDA SE will 
undergo acetate hydrolysis.  
13.1.7.3 Fixation and Detection 
Before fixation, the cells must be washed with PBS or other suitable buffer. Standard 
fixation protocols using aldehyde-containg fixatives  should effectively crosslink the 
amines of the protein-probe conjugate. After fixation, the cells should be rinsed in 
PBS. CFDA SE dye reacts with amine groups and should not be used with amine-
containing buffers or lysine coated slides. 
The approximate excitation and emission peaks of this product after hydrolysis are 
492nm and 517 nm respectively. Cells labeled with CFDA SE can be visualized by 
fluorescence microscopy using standard fluorescent filter sets. 
 
 
 
 
 
